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Abstract
ENHANCING ADOPTIVE CELL THERAPY BY AUGMENTING FITNESS AND ANTITUMOR FUNCTION OF TUMOR-INFILTRATING LYMPHOCYTES
Parin Mahir Shah, M.S.
Advisory Professor: Anirban Maitra, M.B.B.S
Co-Advisory Professor: Chantale Bernatchez, Ph.D.
The success of immune checkpoint inhibitors (ICIs) has established the
importance of cancer immunotherapy in solid cancers, where it has been adopted as one
of the standards of care for advanced melanoma and lung cancer. It is currently being
investigated to treat other solid cancers. However, a large fraction of patients do not
respond to ICIs and relapse. ICI therapy offers an in vivo approach to activate tumorspecific T cells, albeit in some cases, this modality does not create a sufficiently robust
anti-tumor response. Thus, ex vivo approaches employing manipulation of immune cells,
such as Adoptive Cell Therapy (ACT) using autologous Tumor-infiltrating lymphocytes
(TILs), might be able to provide therapeutic benefit. TILs are selective tumor antigentargeted T cells that can be expanded from freshly resected tumor tissue and reinfused
to the patient through ACT as an anti-tumor therapeutic modality. At MD Anderson, we
have observed a response rate of approximately 42% to autologous TIL therapy
treatment for Metastatic Melanoma (MM) patients. Learning from MM, we implemented
and improved on our ex vivo TIL expansion method for Non-small Cell Lung Cancer
(NSCLC), employing a three-way stimulatory approach using an agonistic CD3 (TCR
stimulation), 4-1BB (co-stimulation) antibodies and IL-2 (cytokine support), an approach
referred to as “TIL 3.0”. We demonstrated the feasibility of robustly expanding a T-cell
repertoire recapitulating the clonal hierarchy of the T cells in the NSCLC tumor, including
a large number of putative tumor-specific TIL clones, using this TIL 3.0 methodology.
Success of TIL-ACT also depends on the capacity of infused TIL to thrive and
elicit anti-tumor activity after re-infusion. Infused TILs can migrate to the tumor milieu,
but long-term persistence and efficient tumor killing are essential to eradicate tumor.
Multiple solid cancers create a hostile tumor microenvironment (TME) for optimal T-cell
persistence through various mechanisms. One such mechanism involves TGFβ, a
pleiotropic cytokine secreted by the majority of solid tumors that has been shown to
suppress TIL functionality and is associated to resistance to immunotherapy.
Additionally, TILs can face a deficit of essential co-stimulatory and cytokine growth
signaling in the TME, which may limit their effector function in vivo. My work
demonstrated that TILs engineered to express a TGFβ-chimeric antigen receptor (TGFβCAR) can not only block inhibitory TGFβ signals, but also convert it to stimulatory signals
for TIL persistence and activation. Here, TGFβ-CAR is designed to support and enhance
the natural TCR activity of the TILs, while capitalizing on the multitude of tumor antigens
recognized by TILs to prevent tumor immune escape, as opposed to the typical singleantigen targeted CARs. Therefore, these innovative approaches can consistently
generate a TIL-ACT product with enhanced tumor specificity and provide the required
co-stimulation and cytokine support at the TME to achieve a potent anti-tumor immunity.
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Chapter 1 : Introduction
The immune system is a vast complex of proteins and cells whose primary role
is to defend the body against diseases and infections. Although most advances in
immunology have occurred in the past century, the fact that surviving an infectious
disease confers greater immunity against the disease had been suggested by the
ancient Greeks. The beginning of Immunology as a science is usually attributed to
Edward Jenner in the late 18th century, when he demonstrated that inoculating a healthy
individual with weakened or mild disease-causing strains of cowpox confers resistance
against a deadlier disease (in this case, smallpox), thereby creating the first vaccine [1].
Louis Pasteur, Robert Koch, Emil von Behring and Shibasaburo further expanded
Jenner’s work and provided empirical evidence for generating an immune response
against pathogens [1]. However, the first actual understanding of these mechanisms
was provided by Elie Metchnikoff and Paul Ehlrich. Metchnikoff discovered phagocytic
cells that are always present in the blood and kill microorganisms. He termed such cells
as macrophages. Ehlrich’s research established that neutralizing antibodies could be
induced against an extensive repertoire of foreign proteins present on pathogenic
microorganisms and he named these proteins “antigens”.

Since then, our

understanding of immune system has grown exponentially and has allowed us to
harness its huge potential in treating several diseases.
1.1: Tumor Immunology Concepts
Cancer has the second highest mortality in the world at present. The World Health
Organization estimated a 19.3 million new cancer cases and almost 10 million cancer
deaths occurred in 2020 [2].The National Cancer Institute defines cancer as “An
abnormal mass of tissue that forms when cells grow and divide more than they should
1

or do not die when they should.” Our immune system that is trained to recognize and
eliminate pathogens finds it challenging to tackle these aberrantly dividing ‘self’ cells.
Ehlrich introduced the concept of the capacity of immune cells to differentiate the body
(self) antigens from pathogenic (non-self) antigens in 1909 [3]. He is also credited with
proposing the role of immune system in aiding both tumor control and clearance,
hypothesizing that the host’s immune system prevents the aberrantly-dividing cells from
becoming cancerous [3]. However, he could not prove this experimentally. The first
experimental proof of the immune system’s role in cancer control was demonstrated by
Ludwik Gros when he reported that mice immunized intradermally with a sarcoma tumor
line were conferred protection against it when re-challenged with the same cells [4].
Frank Maclane Burnet and Lewis Thomas in the 1950’s proposed the theory of
immunosurveillance of cancer; the immune system surveilles the tumor, recognizes
neoantigens arising because of genetic aberrations and eliminates such malignant cells
[5, 6]. However, it was only in the 1990s when Robert Schreiber and colleagues showed
that mice lacking fully functional immune systems were more susceptible to tumor
formation and growth, thereby proving Elhrich’s theory of tumor control by immune cells
elaborated in 1909 [7-9].
The ability of tumor cells to continue dividing unhindered in the presence
of immunosurveillance led to revision of this theory and introduction of the notion of
“immunoediting” [10]. Immunoediting encompasses four phases as depicted in Figure
1, describing an intricate relationship balance between tumor cells and immune cells;
elimination, equilibrium and escape [10]. The first step is the cancer initiation. The
second

phase,

elimination,

is

synonymous

with

the

previous

theory

of

immunosurveillance, where the immune cells recognize and eliminate the majority of
2

tumor cells. However, some tumor cells start acquiring a resistant phenotype [10]. In the
third phase, the equilibrium, the tumor cells and the immune system reach a state of
dormancy where the immune cells keep the tumor cells in check, but do not completely
eliminate them [10]. This may be the longest of all the three phases and it is likely during
this phase that tumor cells would further acquire mutations to resist immune pressure
[10]. In the final stage, immune escape, these tumor cells that have evaded immune
pressure would now continue to survive and proliferate in an immunologically intact
environment [10]. Immune escape mechanisms may result from genetic aberrations in
the tumor cells itself or the tumor microenvironment (TME). In this following chapter, I
will introduce how the immune system recognizes and mounts an immune response
against an antigen (Figure 1).

3

Figure 1: Stages of Cancer Immunoediting
The first stage in the process is the cancer initiation that arises due to carcinogenesis,
radiation. The next stage is the Elimination, where the immune cells starts recognizing and
destroying the tumor cells. Immune cells can either successfully kill all the tumor cells and
resolve cancer or they attain a stage of Equilibrium. Here, the tumor cells and the immune
system reach a state of dormancy where the immune cells keep the tumor cells in check,
but do not completely eliminate them. At this stage, the immune cells apply a selective

pressure and only allow the survival of tumor cells that are resistant to this immune pressure.
Over a period, tumor cells accumulate more mutations and further create a
microenvironment that is conducive to tumor growth and suppress the immune components.
In the final stage, these immunologically resistant tumor cells cannot be controlled by the
immune cells. Thus, they Escape this immune pressure and expand ferociously. Adapted
from “Stages of Cancer Immunoediting”, by BioRender.com (2021).

1.2: Initiation of Adaptive Immune Response, T cell memory and T cell
dysfunction:
1.2.1: T-cell Antigen recognition, activation and differentiation
Adaptive immune system consists of specialized cells called lymphocytes that
arise from a common lymphoid progenitor (CLP), that is derived from Hematopoietic
Stem Cells [1]. T and B cells are the two cell components that make up the adaptive arm
of the immune system. The adaptive immune system is organized around the
4

recognition and elimination of non-self or foreign antigens. Antigens are substances that
can elicit an immune response. The two major immune cell types, B cells and T cells,
express an antigen receptor on their surface; the T-Cell Receptor (TCR) or the B-Cell
Receptor (BCR). This receptor is hypervariable. Each cell bears a unique receptor
recognizing a specific antigen. The receptor will be passed on to the daughter cells when
the cell divides, and the resulting population will be referred to as clonal because they
possess the same unique receptor. Unlike innate system, adaptive system consists of
diverse receptors that enable it to recognize a broader repertoire of antigens. This is due
to two reasons: 1) A recombinant V(D)J process that produces random genetic
recombination of segments responsible for receptor affinity thus giving rise to an unique
clone and infinite combinations of such unique antigen receptors and 2) Somatic
hypermutation, a process that brings about accelerated mutations in the TCR or the
antibody producing gene of lymphocytes thereby giving rise to antibodies with novel
affinities [11]. Another unique aspect of adaptive immunity is that immunological memory
is created against an antigen after the first encounter and results in a quick and profound
response on re-encountering the antigen.
The T-cell receptor on the surface of a CD8+ T cell recognizes antigenic peptides
in complex with a molecule of major histocompatibility class I (MHC I), while TCR from
CD4+ T cells recognize antigenic peptides complexes to MHC class II molecules [1].
Endogenous proteins produced by the cells, are broken down into small peptides of 912 amino acids in the proteasome, which are then loaded onto MHC I proteins (present
on all nucleated cells) in the endoplasmic reticulum and shuttled to the cell surface [1214]. The peptide loaded in the groove of the MHC class I protein may come from
endogenous antigen presentation as detailed above or alternatively, extracellular
5

antigens from cell debris from dead tumor cells or dying tumors can be taken up by
professional Antigen Presenting Cells (APC) such as Dendritic Cells and be processed
and cross-presented as peptides on MHC I and MHC II molecules [13] (Step 2, Figure
2). Tumors express a multitude of antigens from mutated self-proteins to over-expressed
tissue-restricted or differentiation antigens. Peptides derived from such proteins can be
recognized by the naive CD8+ T cells as foreign and elicit anti-tumor response as the
first step in Figure 2. Three distinct signaling events are required for optimal T-cell
activation and response, in order to overcome the signaling/activation threshold
enabling full activation and the acquisition of effector functions. The first signal is
provided when the T-cell recognizes the peptide:MHC I complex through its TCR,
initiating the TCR signaling cascade. The strength of the TCR signaling cascade
depends upon the affinity and the specificity of the TCR towards the cognate antigen.
The CD8 co-receptor stabilizes the peptide:MHC I and TCR interaction [15]. DCs
encounter antigens, get activated, upregulate expression of surface co-stimulatory
ligands such as CD28, 4-1BB and secrete cytokines while migrating to nearby lymph
nodes (Step 3, figure 2) [16-18]. Co-stimulatory ligands serve as the second signal in Tcell activation as they potentiate the initial TCR activation by aiding the recruitment of
the signaling molecules that relay the downstream TCR signaling cascade. Costimulatory signals are essential, and a T-cell primed without it may lack functional
activation or become anergic [17]. Lymph nodes are secondary lymphoid tissues located
across the body full of innate and adaptive immune system cells. DCs trafficking to
lymph nodes will present the antigens to T cells concomitantly with the co-stimulatory
molecules (signal 2) (Step 4, figure 2). The third signal is provided by the cytokine milieu

6

that polarizes the T cells towards either an inflammatory Th1 or anti-inflammatoryTh2
phenotype based on the cytokines they secrete.
On receiving all these three signals, the activated CD8 T cells would proliferate,
starting the clonal expansion where a single clone can proliferate 1000-fold [19], leave
lymph nodes and traffic towards the cancer site (Step 5, figure 2). Upon reaching the
cancer site, CD8+ T cells can detect the antigens presented on the cell surface through
peptide:MHC I and TCR interaction and kill those cells presenting the antigen their TCR
is specific for through granzyme and perforin (step 1, figure 2) and thus the cycle
continues [1]. Perforin pokes hole in the cellular membrane of the targeted cells causing
the intracellular contents to leak out [1]. Granzyme b is a protease that brings about
DNA degradation, resulting in cell apoptosis [1]. CD8+ T cells can also mediate their
cytotoxic functions through FAS Ligand: FAS interactions, triggering a caspase cascade
in the target [20]. CD8+ T cells also mediate killing through secretion of the effector
molecules IFN-γ and TNFα [1].

7

Figure 2: Tumor-specific T cell Induction and function
During oncogenesis, cancer antigens can be released in step (1), that would be

phagocytized by dendritic cells, processed and presented on the cell surface in step (2).
DCs would then migrate to the lymph node in step (3) and present antigens to the naïve T
cells along with co-stimulatory molecules as in step (4). This would activate the T-cell and
they start to proliferate. These activated T cells would then leave the lymph nodes and
home towards the tumor site in step (5). Once, at the tumor site, the T cells would mediate
tumor killing upon recognition of its cognate antigen and the cycle repeats. Adapted from
“Tumor-specific T cell Induction and Function”, by BioRender.com (2021).

After achieving tumor clearance, around 90-95% of the T-cells involved in the
immunological response undergo apoptosis because of lack of cytokine support and
absence of antigens. The remaining small percentage of the T cells differentiate into
long-lived memory cells that persist either in the blood or at the tissue site and quickly
response if they encounter their cognate antigen again. One of the hallmarks of adaptive
immunity is the generation of this immunological memory that persists for a long-time
8

without antigen activation through Il-7 and IL-15 mediated self-renewing homeostasis
[21]. Multiple factors such as the duration and the strength of TCR stimulation, the
cytokine milieu, transcriptional and epigenetic factors, metabolic modulators and a
disparate segregation of lineage-determining factors determine the fate of the CD8 T
cells. In addition, each cell is exposed to a different strength and duration of such factors
spatially and temporally, resulting in a heterogenous effector and memory cell
population [22]. Ultimately, expression of certain markers and surface receptors such as
Bcl-6, Eomes, STAT3, IL-7Rα, CD62L and IL15Rβ among others are associated with
generation of memory while certain other markers are associated with terminal
differentiation (PD-1, T-bet, KLRG1, Blimp-1) [22, 23]. Cells that transition successfully
to memory phenotype may form one of the following subsets of T cell memory - stem
cell, central, effector or tissue resident. Each of the subsets has its own individual
functionality, phenotype and tissue localization [22, 24-26].

1.2.2: T-cell dysfunction in cancer
In cases such as chronic viral infection or cancer, T cells tumble into a state of
dysfunction, that is characterized by poor effector function, loss of proliferative potential,
constitutive surface expression of inhibitory receptors and a distinct transcriptional state
disparate from effector or memory T cells (Figure 3) [27]. Two major themes have
emerged extending our understanding of T cell dysfunction. The first being our improved
understanding of the key roles played by cell-extrinsic negative regulatory pathways
mediated by immunosuppressive cytokines such as TGFβ, IL-10 and cell-intrinsic
negative regulatory pathways mediated by inhibitory receptors such as PD-1, CTLA-4,
TIM-3 etc. The second theme that has emerged is the comprehensive molecular
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characterization of the T cell dysfunction. Understanding of these mechanisms is
quintessential in preventing (autoimmunity) or rejuvenating T-cell functionality. IL-2
production is the first effector function that is lost by an effector T cell after undergoing
chronic antigen stimulation [28]. This is followed by a decrease in TNFα and IFN-γ
production [28]. Additionally, these dysfunctional cells express lower levels of CD69 and
CD127, markers typically associated with effector T cells [29]. Infections or response to
tumor elicits a response mediated by multiple epitope-specific T cells due to recognition
of multiple antigens and subsequent epitope spreading. Epitopes or antigenic
determinants are the portion of an antigen that elicits an immune response. Epitope
spreading is defined as the diversification of epitope specificity from the initial to new
epitopes as a result of cross presentation that evolves with the immune response [30].
Since each T-cell is unique and specific to a particular antigen, each cell also has a
different threshold to become dysfunctional [28]. However, such dysfunctional T cells
rarely are physically deleted, and a large proportion of such antigen-specific T cells
persist in the microenvironment devoid of effector functions. Active research is ongoing
to find methods to reverse this exhaustion and other ways that this knowledge can be
utilized to harness an effective anti-tumor response.
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Figure 3: Hierarchical T cell dysfunction during chronic infection/cancer
Naïve T-cells primed with antigen recognition and co-stimulation from DCs differentiate into
effector T cells. Activation causes T cells to proliferate and divide into a clonal subpopulation.
If the antigen is cleared, most of these effector cells undergo apoptosis. However, a small
percentage differentiate into polyfunctional memory cells capable of producing multiple
cytokines such as IFN-γ, TNF and IL-2 (top row). Such memory cells can persist for a long
term without antigenic stimulation. However, during cancer, a tumor suppressive
microenvironment coupled with antigen persistence pushes T cells through a myriad of
dysfunctional stages with ultimately leads to T cells losing effector functions as the
dysfunctional stage progresses. This is accompanied by increased and varied expression of
multiple inhibitory receptors. In rare circumstances, when the severity of antigenic stimulation
is high and the duration is prolonged, it may result in total elimination of antigen-specific T
cells. T cell dysfunction can be judged by inhibitory receptor expression and loss of effector
function. Figure adapted from John Wherry and used with approval from Copyright Clearance
Center License number 5182121153684.
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To summarize, T cells play a pivotal role in eliciting immunity against tumors. The
degree of T-cell infiltration in solid tumors generally correlates to improved prognosis in
multiple solid cancers [31]. As reviewed in the above sections, T cell population is
heterogenous. Their ability to control tumor, develop immunological memory or become
exhausted is also a function of their heterogeneity. Much is known about the role of T
cells in clearing infections and great strides are made in dissecting its interactions in the
tumor microenvironment (TME), how the TME affects them and how to overcome the
functional impediments governing their cytotoxic potential. They also play a vital role in
shaping the tumor immunogenicity and the immune landscape of the cancer.
Understanding these aspects is essential to harness their full wrath to both prevent and
cure cancer. This has launched an immunotherapy revolution which is introduced in the
next section.

1.3: Immunotherapy of Cancer
National Cancer Institute (NCI) defines Immunotherapy as a “substance that either
inhibits or stimulates the immune response to fight cancer, infection or other disease”.
Dr. Bruns was one of the earliest pioneers of cancer immunotherapy when in 1888, he
observed that infections can be beneficial to cancer patients and can mediate cancer
regression. He further reported that injecting erysipelas causing bacteria resulted in
tumor shrinkage in his patients [32]. Dr. William Coley furthered the cancer
immunotherapy work in 1891, when he reported that injecting pathogenic bacteria
(Coley’s toxin) into long bone sarcoma patients, caused tumor regression through
activation of their immune system [32]. Progress was stymied till the discovery in 1976
that the T-cell growth factor, IL-2 can mediate tumor eradication and IL-2 has been used
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as a therapeutic modality for metastatic melanoma ever since [33]. In 1988, it was
further shown that cellular therapies entailing infusion of patients’ own ex vivo expanded
autologous T cells mediate tumor regression [34]. This field of Adoptive cell therapy has
evolved and now includes functionally-enhanced genetically modified T cells such as
Chimeric Antigen Receptor T cells (CAR-T). Further, discoveries on T-cell activation and
functionality culminated in the development of antagonistic antibodies against inhibitory
receptors on T cells, so called “immune checkpoint inhibitors” and agonistic antibodies
to co-stimulatory molecules. Immunotherapy development focuses on overcoming
barriers of TME or functional aspect of T cells. Notable advances in immunotherapeutic
approaches for cancer immunotherapy are discussed below.

1.3.1: Cytokine Therapy
As mentioned previously, identification of IL-2 as a T-cell growth promoter spurred the
field of modern immunotherapy [33]. Dr. Steven Rosenberg in 1984, demonstrated the
therapeutic potential of systemically administered IL-2, wherein a patient had total tumor
regression (complete response) that has continued for over 30 years [35]. This was the
first example of an effective immune response to cytokine therapy and hinted at the
possibility of durable responses. His pioneering work and multiple follow up studies
resulted in Food and Drug Administration (FDA) approving high dose IL-2 as a treatment
regimen in renal cancer (20% overall response rate) in 1992 and metastatic melanoma
(16% Overall Response Rate (ORR) in 1998 [35]. IL-2 has a very short half-life and to
overcome this challenge, PEGylated form of IL-2 was investigated. PEGylated IL-2
shows an enhanced safety and pharmacodynamic profile and is actively investigated
with other immunotherapies as a combination regimen [36]. High dose of IL-2 causes
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toxicity in most organ systems including lungs, kidneys, heart and central nervous tissue
and significant dose-related morbidity [37, 38]. One way to overcome this, was to use a
lower dose or prolonged infusion that improved IL-2 tolerability, but decreased response
rate as well [38]. Another cytokine, that showed promise is the type I interferon IFNα. It
is secreted by multiple immune cell fractions and elicits both anti-viral and anti-tumor
response. It induces MHC I expression on tumor and activates immune cells [1]. It was
first approved by FDA in 1995, after it was found to cause significantly longer relapsefree survival to cutaneous melanoma patients in an adjuvant setting [39]. However, due
to its toxicity and availability of a novel immunotherapy class of drugs (like CBI), its use
was discontinued. There are several cytokines under active investigation, such as IL-7,
IL-15 and IL-21. IL-7 and IL-15 promote expansion of memory T cells and are crucial for
T cell homeostasis [40]. IL-21 both activates and expands CD8 cytotoxic T cell
population [41]. While IL-2 and IFNα are the only FDA approved cytokines at present,
early clinical trials of IL-7, 15 and 21 show promising clinical activity [41-43].

1.3.2: Immune checkpoint Inhibitors
When T cells become activated, they upregulate several co-stimulatory receptors (signal
2) that help them sustain and potentiate their cytotoxic potential. T cells also start
upregulating inhibitory molecules to equipoise the activation [44]. These inhibitory
receptors are commonly referred to as immune checkpoints and they play a vital role in
disease-free conditions or after clearing infection, efficiently shutting down the immune
response [45]. These molecules modulate both the strength and length of the immune
response preventing unusual self-recognition or autoimmunity [46, 47]. Immune
checkpoint inhibitors (ICIs), also called checkpoint blockade immunotherapy,
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encompass all the antagonist antibodies against these immune checkpoints. At the
moment, anti-CTLA4 and anti-PD-1 antibodies are approved for therapeutic use, but
antibodies targeting other checkpoint molecules such as Tim-3, Lag3, TIGIT or others
are in development. When ICIs engages their cognate ligand/receptor, they disrupt the
binding of the checkpoint molecule to its natural ligand preventing inhibition of the T cell
and thus unleashing its optimal cytotoxic potential [45]. Tumor cells effectively subdue
immune response by upregulating such immune checkpoints themselves or by recruiting
cellular fractions to TME that expresses ICs. Some of the key immune checkpoints that
are therapeutically targeted are described below.

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
TCR:MHC engagement signals T-cell specific recognition of its target. However, for
optimal T cell activation, co-stimulatory signals are essential. Once such interaction
happens between, for example, B7-1 (CD80) or B7-2 (CD86) on the APCs and CD28
on T cells, thereby triggering T cell proliferation, survival, differentiation and secretion of
IL-2. The T-cell activation is terminated by the engagement of negative regulators that
are upregulated to the T-cell surface in a coordinated fashion after activation. CTLA-4 is
a CD28 homolog with a much higher binding affinity and competes with CD28 for
engagement to B7 molecules [48, 49]. CTLA-4 exists both on the cell surface and as an
internal reservoir beneath the cell membrane [50, 51]. CTLA-4 is typically expressed at
low levels in naïve cells and is upregulated on activation [50, 51]. Hence, majority of the
CTLA-4 expression is found on the activated Effector T cells [44]. Both the variability
and the surface concentration of CTLA-4 is a directly dependent upon the intensity of
TCR activation [52]. A strong stimulus enhances CTLA-4 trafficking to the cell surface
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[52]. IFN-γ and IL-2 stimulation also upregulates surface CTLA-4 expression
independently of TCR stimulus [53]. FoxP3 is the major transcriptional factor of
regulatory CD4+ T cells (Tregs) and also mediates CTLA4 transcription, hence Tregs
shows a constitutive CTLA-4 surface expression [54]. The relative comparison of
CD28:B7 binding v/s CTLA4:B7 binding decides the fate of T-cell with it either
undergoing activation or anergy [48]. Furthermore, some evidence suggest CTLA-4
engagement with B7 molecules may directly inhibit T-cell activation by inhibiting the
CD28 signaling or increasing T-cell mobility, decreasing the ability of T cells to interact
with APCs [55, 56]. These Tregs can snatch and degrade the B7 molecules on APCs
through trans-endocytosis, that prevents APCs from activating other immune
components for their lack of co-stimulatory B7 molecules [57]. Thus, blockade of CTLA4 will ameliorate T-cell function and rescue them from CTLA-4 mediated
immunosuppression. Dr. James Allison first reported that CTLA-4 blockade enhanced
tumor clearance in mice and this led to development of a fully humanized anti-CTLA4
antibody, Ipilimumab [58]. CTLA-4 functions during the T-cell priming phase in the lymph
node. CTLA-4 blockade supports sustained T-cell activation and proliferation of effector
T cells, increases diversity of peripheral T-cell pool and reduces Treg mediated immune
suppression [59]. Ipilimumab showed survival benefits in advanced metastatic
melanoma patients, and it was approved by FDA in 2011 [60].

Programmed cell death protein 1 (PD-1)
PD-1 is another checkpoint molecule and is upregulated on activation and is present at
extremely minuscule levels on Naïve T cells [61]. It has two ligands: PD-L1
predominantly found on tumor and DCs, PD-L2 found on macrophages and DCs [62].
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PD-L1 can also be expressed on T-cell after TCR activation or following exposure to
cytokines such IFNγ, GM-CSF and IL-4 [62, 63]. PD-1 inhibits T-cell at effector stage
where it acts through its ITIM and ITSM inhibitory cytoplasmic domains and
dephosphorylates the TCR complex and CD28, thereby diminishing T-cell function,
survival and proliferation [64]. Furthermore, the cytotoxic activity (IFN-γ secretion) of T
cells upregulates PD-L1 expression on tumor [65]. These reasons prompted
development of both anti-PD1 and anti-PD-L1 antibodies and the first drug in class was
approved by FDA in 2014 for treatment of Melanoma. Since then, its use has expanded
to multiple solid cancer types such as Renal cancer and NSCLC and cancers with high
microsatellite instability [66, 67].
Due to success of these two immune checkpoint inhibitors, several other
checkpoints have since been discovered and targeted. Second generation inhibitors
(Lag-3, Tim-3 and TIGIT) and even third generation inhibitors (VISTA and BTLA) have
been explored either as monotherapy or in combination with CTLA-4 or PD-1 [40, 44].

1.3.3: Costimulatory activation of T cells
As described previously, co-stimulatory molecules provide signal 2 of T-cell activation
and amplify the initial TCR signal, thus influencing T cell fate and differentiation [68-74].
For the purpose of this thesis, I will be focusing on the costimulatory molecules 4-1BB
and ICOS.

1.3.3.1: Inducible co-stimulatory molecule (ICOS)
ICOS or CD278 is a co-stimulatory receptor in the Immunoglobulin family like
CD28 [75]. As the name suggests, ICOS expression is induced on T cell activation and
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it binds to its cognate ligand ICOS-L, expressed on APCs [72]. ICOS is expressed on
both activated CD4 and CD8 T cells but predominantly on CD4 T cells [76]. ICOS shares
a large degree of homology to CD28 and like CD28 signaling, ICOS engagement with
ICOS-L leads to PI3K recruitment ultimately culminating to AKT activation and promotes
cell survival and proliferation [75, 77]. However, ICOS stimulation is less potent than that
of CD28 because it cannot recruit the Grb-2 domain and thus can only induce a limited
IL2 production [78]. ICOS stimulation promotes T cell production of IL-10, IL-4 and IL21 that are essential for development and maintenance of Tfh, Th2 and Th17 cells in
humans [79]. ICOS transmembrane domain recruits Lck and augments TCR-triggered
calcium mobilization that drives CD40 L externalization and subsequently enhances
interactions with B cells [80]. Tfh cells play a critical role in activating B cells and
formation of germinal centers (GCs) [81]. Depletion of ICOS has resulted in severe
defects in B-cell memory and GC formations [81]. An ICOS agonist monoclonal antibody
is currently being evaluated in advanced refractory solid tumor malignancies as
monotherapy and in combination with Nivolumab (anti-PD1) [81, 82]. In an interesting
approach, intratumoral modulation of ICOS by a recombinant oncolytic virus
demonstrated systemic anti-tumor immunity in mice models [83].
ICOS plays a critical role during the secondary antigen exposure [84] and hence
ICOS is extensively being evaluated is the CAR field. CARs incorporating ICOS
signaling domain demonstrated a greater enhancement of PI3K activation than 4-1BB
[85]. Furthermore, ICOS costimulatory domain resulted in greater polarization of
Th1/Th17 T cells with increased secretion of IFN-γ, IL-17 and IL-22 [79]. Human Th17
cells expressing a CAR molecule incorporating an ICOS costimulatory domain, exhibited

18

enhanced antitumor activity and persistence when compared to CD28 or 4-1BB
incorporating CARs [86].

1.3.3.2: 4-1BB
4-1BB or CD137 is a co-stimulatory receptor in the Tumor Necrosis Factor
Receptor (TNFR) family. Its expression is primarily restricted to cytotoxic CD8+ T cell
[87]. However, its expression is upregulated following activation [87]. In addition, 4-1BB
is also found on NK cells, APCs and T regs [88-92]. 4-1BB engages with its trimeric 41BB ligand on APCs and recruits TNFR-associated factor family members such as
TRAF 1, 2 and 3 forming the 4-1BB signalosome. These TRAF molecules propagate
downstream signaling through MAPK, ERK and NF-κB [93].
NF-κB signaling upregulates anti-apoptotic genes such as BCL-2 and BCL-XL,
inhibits Activation-induced cell death (AICD) and promotes cell cycle progression [94,
95]. 4-1BB engagement also potentiates T-cell effector functions. It increases IL-2 and
IFN-γ secretion of CD8+ T cells and IL-2 and IL-4 in CD4+ T cells [96, 97]. 4-1BB
preferentially supports CD8 T cell expansion through delayed PI3K/ERK/AKT signaling,
and by activating the T-cell factor 1/ beta-catenin pathway associated with preferential
CD8 T-cell proliferation [98, 99]. Thus, 4-1BB engagement skews T cells towards a Th1
polarization [100, 101]. Owing to all these properties, potent anti-tumor activity has been
reported in both murine and in clinic using agonistic 4-1BB monoclonal antibodies [102].
Chief among them were Urelumab by BMS and Utomilumab by Pfizer [103]. Urelumab
showed impressive anti-tumor activity, but the clinical trials had to be halted due to
severe hepatotoxicity [103]. Utomilumab was administered at lower dosage to avoid
hepatotoxicity, but suffered from a lower overall response rate [103, 104]. Murine models
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demonstrated that administering checkpoint inhibitor (anti-CTLA-4) with agonistic anti4-1BB antibody would alleviate some of the toxicity [105]. However, combined targeting
of PD-1 and 4-1BB exacerbated hepatoxicity and brought clinical trials to a halt [106].
Even though 4-1BB failed in clinic, its potential did not go unnoticed, and it was
immediately incorporated to enhance cellular immunotherapy for cancer, particularly in
ACT involving TIL and Chimeric Antigen Receptor (CAR). 4-1BB agonistic antibody
(Urelumab) addition to tumor fragments resulted in robust expansion of TIL from PDAC
resection, in addition to preserving a TCR repertoire observed in original tumor resection
[107]. Furthermore, utilizing the three signal approach to expand TIL where TCR
stimulation (agonistic CD3 antibody), a costimulation (4-1BB antibody) and cytokine
support provided by IL-2 resulted in improved T-cell yield, preferentially of cytotoxic CD8
T cell in a short period while preventing over differentiation in melanoma, uveal
melanoma and non-small cell lung cancer (discussed in detailed in chapter 3 of the
thesis) [107-109]. 4-1BB further prevents AICD of TIL in culture, when millions of TIL
are expanded to billions through Rapid expansion protocol and improves its effector
potential [110, 111].
Another field where 4-1BB is incorporated is in CARs. CARs incorporating 4-1BB
demonstrated enhanced production of IFN-γ, granzyme B, TNFα and of the antiapoptotic proteins BCl-6 and BCL-XL [112]. This approach prolongs T cell division
thereby enhancing cell persistence and anti-tumor activity [113]. It further favors CD8+
central memory formation with T cells exhibiting higher respiratory capacity and
mitochondrial biogenesis as opposed to a glycolytic metabolism favored by CD28
engagement [114]. Autologous T cells expressing a CD-19 CAR incorporating a 4-1BB
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domain have been approved for treating refractory B-ALL and show a longer persistence
when compared to CD28 domain [115-117].

1.3.4: Cellular Immunotherapy for Cancer
Adoptive T-Cell Therapy encompasses, isolating and expanding tumor-specific T cell for
infusion back to the patient as a therapeutic modality for cancer. Dr. Steven Rosenberg’s
work on T-cell ACT started the ACT revolution when he first infused autologous TIL
expanded ex vivo in metastatic melanoma patients with high dose of IL-2 [118]. Since
then, the ACT field has expanded and flourished to include developments such as
Endogenous T-cell Therapy, genetically engineered T cells [TCR and Chimeric Antigen
Receptor (CAR)], as well as NK cells [119]. As pertinent to this thesis, I will be focusing
on ACT of TIL and Chimeric Antigen Receptor modified T cell Therapy for cancer
treatment in the next section.

1.3.4.1: Adoptive cell therapy with tumor-infiltrating lymphocytes
T cells infiltrate tumors and the degree of this infiltration correlates with better
clinical outcome [120-124]. Adoptive cell therapy with TIL (TIL-ACT) comprises of two
stages; the first one involves resecting the tumor, mincing it into small fragments and
propagating the TIL obtained from the resected tumor tissue with IL2 [125], which is
termed as Pre-Rapid Expansion Protocol (Pre-REP). Following Pre-REP, the TIL
undergo a second round of expansion called Rapid Expansion Protocol (REP) where
they are expanded to billions, pooled and infused back to the patient to control the tumor
[126]. Dr. Rosenberg and his colleagues tested this approach in murine models of
lymphoma and reported better outcomes with systemic IL-2 administration [127-129].
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They followed this with the first autologous TIL-ACT clinical trial in metastatic melanoma
patients along with high dose of IL2 and reported 34% regression rate, however the
duration of response was short lived and the infused TIL persistence was short [118,
130-132]. TIL-ACT was tolerated well, but the concomitant high dose IL-2 administration
resulted in most of the side effect associated with the ACT [133]. In another
breakthrough, it was reported that prior lymphodepletion with cyclophosphamide before
TIL infusion improved outcomes in murine ACT models of lung metastasis [133]. This
resulted in an NCI study that researched an optimal lymphodepleting regimen prior to
TIL-ACT and currently cyclophosphamide and fludarabine are the most widely used
lymphodepleting regimen for TIL-ACT [134]. Lymphodepletion depletes T-regs and the
endogenous homeostatic cytokine sinks thus increasing the availability of IL-7 and IL15 to the infused TIL to increase their persistence [135]. A high dose of IL-2 further
supports their expansion [134]. Thus, incorporation of a lymphodepletion regimen and a
high dose IL2 improved response rates to 51% from the previous rate of 34% [130, 136].
In another development, it was reported that responders to ACT were infused
with TIL that had longer telomeres [137]. Thus, a new “Young TIL” culture protocol was
developed which reduced culture time by eliminating the step of testing of TIL reactivity
prior to TIL expansion with the assumption that TIL cultures possessed anti-tumor
activity. This made TIL-ACT accessible to more people while producing a TIL phenotype
with enhanced persistence [137, 138]. A clinical trial tracking “young TIL” observed
improved TIL persistence in the peripheral blood in metastatic melanoma patients with
an overall response rate comparable to previous TIL trials [138].
To further improve TIL-ACT outcomes, it was hypothesized that modifications to
the growth protocol focusing both on the cell culture vessels and the growth factors in
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the culture medium can have a bearing on the phenotype and functionality of the final
infused TIL product. Materials used to culture TIL can not only affect the phenotype of
the final product but can also simplify manipulating cell cultures. This can streamline the
logistics of TIL culture and make TIL-ACT more accessible. A case in point is the
adoption of gas-permeable flasks (GREX) over the traditional use of tissue culture
plates/flasks and gas permeable bags [139]. GREX flasks have a gas permeable
membrane at the bottom of the flasks, where the cells sit thus improving oxygen
availability for the TIL [140]. This simple change enhanced expansion of TIL that failed
to grow in traditional culture methods and improved mitochondrial functions maintaining
clonal diversity [140-142]. GREX further improved the CD8+BTLA+TIL fraction, the
presence of which correlates with TIL persistence and response [143-145]. This can be
attributed to the fact that CD8+BTLA+ TIL are less differentiated when compared to
CD8+BTLA- TIL and can serially kill cancer cells [146, 147].
Further improvement in TIL-ACT culture were brought about with the use of
agonistic antibodies in cell culture. An ACT product with higher number of TIL infused
and a higher CD8 TIL fraction correlated with better response and has been confirmed
in multiple clinical trials [143, 148-152]. Traditional method of TIL expansion employed
high dose of IL-2 (6000 IU/ml) for expanding TIL from tumor fragments. Different groups
reported varied success rate of TIL propagation ranging from 31% to as high as 91%;
with no consistent threshold TIL number to term it a success [139, 153-155]. Such
culture methods also reported a varied CD8+ TIL proportion with an average ~50%
population and which last in culture for around 3 to 5 weeks [137, 143, 150]. Longer TIL
culture times resulted in a TIL phenotype that is more differentiated based on CD27 and
CD28 expression and have shorter telomere length, both factors attributing to lower TIL
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proliferation, persistence and finally a worse clinical outcome [156-158]. To alleviate
these shortcomings, agonistic 4-1BB antibody was incorporated to the culture media.
The advantages of 4-1BB were enlisted in an earlier section. To briefly recapitulate, 41BB has been shown to accelerate and augment CD8+ TIL expansion, prevent AICD in
the REP process and maintaining CD28 expression that has been correlated with longer
telomeres [110, 111, 156, 159, 160]. As previously reported, optimal T cell growth
requires three signals, a TCR, a co-stimulation and cytokine support. Using this
knowledge, an agonistic CD3 antibody was incorporated with agonistic 4-1BB and high
dose IL2 in a GREX (termed TIL 3.0). This greatly improved TIL expansion in a shorter
duration in multiple cancer types such as melanoma, uveal, ovarian, PDAC [107-109].
NCI reports an overall response rate of 56% for TIL therapy in metastatic melanoma
patients with 19/93 (20%) patients enjoying a complete response of more than 3 years
[161]. With ACT being tried worldwide, multiple centers reported response rate between
38-42%, with complete response still constituting around 10-20% of all the patients [148,
150, 162, 163]. TIL-ACT is now being expanded to treat other cancer types such as
cervical and ovarian cancers with varying rates of response [164, 165]. A response rate
of 28% (5 out of 18 patients) was reported in HPV+ cervical cancer, while 2/11 (18%)
HPV- cervical cancer patients responded to TIL ACT [166] . It is now being commercially
explored with Iovance Biotherapeutics reporting 36.4% and 44.4% response rates in
metastatic melanoma and cervical cancer [167]. In 1990s, TIL therapy was tested in
NSCLC Lung cancer and the trial yielded minor survival benefits [168]. Since these
reports, TIL-ACT has substantially evolved in both manufacturing process of the infusion
product and the host pre-conditioning. With these advances, TIL-therapy was again
revisited in NSCLC patients refractory to anti-PD-1 treatment. 3/13 patients responded
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and the other 11 patients showed some reduction in tumor burden, TIL-ACT shows
promise to conduct a further larger clinical trial [169].

1.3.4.2: Chimeric-antigen receptor T cell therapy
CAR T cells are T cells engineered to express a synthetic antigen receptor
comprised of an extracellular antibody region that recognizes a tumor antigen which is
linked via a stalk to the transmembrane and intracellular domains that triggers a
cytotoxic response upon recognition of the antigen [170]. The tumor antigens recognized
by CARs have to be on the cell surface, completely bypassing MHC processing
requirements of typical T-cell recognition. CAR-mediated antigen recognition benefits
from the high affinity interaction of the antibody with its antigen but cannot target
intracellular antigens. Recently, CARs have been developed with affinities towards
MHC-peptide complexes, opening the door to recognition of intracellular tumor antigens
by CARs [171]. One of the advantages of CARs that recognize such complexes is their
affinity. TCRs that recognize self tumor-antigens usually have a 1.5 log lower affinity
towards their cognate MHC:peptide complexes when compared to the TCR that
recognize MHC:viral peptides [172]. The first synthetic/chimeric TCR CAR was reported
in 1989 and it could transmit T-cell activation signals and gain of effector functions upon
recognizing 2,4,6-trinitrophenyl (TNP) peptide on solid cancers [173]. Following this
report, Irving and Weiss demonstrated that a CAR composed of CD8 and CD3ζ chain
could relay TCR signaling independent of the endogenous TCR recognition [174].
Traditionally, a CAR is composed of an extracellular domain consisting of a
single-chain variable fragment (ScFv) that recognizes the antigen and comprises of
variable heavy (VH) and variable light (VL) chain of an antibody fused together by a
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spacer/linker molecule of ~15 amino acids (Figure 4) [175]. Orientation of the variable
regions within the ScFv (VH - linker- VL or VL- linker- VH) may impact the CAR expression
on the cell surface and the ScFv recognition of the targeted antigen [176]. The
composition and length of the linker chain binding the variable region further determines
the stability of the CAR molecule [176]. Linker chains can result in clustering of the CAR
molecules thereby causing antigen independent or tonic signaling [177]. Certain linkers
such as whitlow linker (GSTGSGSKPGSGEGSTKG) impart proteolytic stability to the
CAR molecule and can further enhance ScFv affinity and potentially alter CAR function
[178]. The ScFv region incorporates the hypervariable CDR3 region and thus
determines the specificity of the antibody, the affinity and consequently regulates the
extent of T-cell activation. Tumor cells glycosylate tumor associated antigens (TAAs)
differently from normal healthy cells and this glycosylation pattern can be discriminated
by ScFv. Indeed, ScFv can be directed against specific epitopes specifically
glycosylated in the as in the case of 5E5 ScFv that specifically targets the glycosylated
GSTA epitope of MUC1 found in the many epithelial cancers [179, 180]. Additionally,
ScFv affinity can be modulated through mutagenesis of the complementary determining
region while not changing the epitope recognized. This mutagenesis alters the strength
of T cell signal and allows a CAR to distinguish the over expressed TAAs on cancer cells
from the normal expression in healthy cells [181, 182]. Using this principle, trastuzumab
(anti-HER2)-based

CAR-T cells

with

lower

ScFv

affinity

could

lyse

HER2+ overexpressing breast cancer cells while sparing the healthy cells with normal
HER2 expression [182]. These results signify that modulating ScFv can influence both
the specificity and differential targeting of an antigen expressed on tumor vs healthy
cells.
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ScFV region is connected to the transmembrane domain with a hinge/stalk.
Historically, majority of the CAR designs incorporate a hinge region made from an
immunoglobulin (IgG) domain. The hinge region imparts stability to the CAR surface
expression and modulates its cytotoxic potential, while providing flexibility to access
targeted epitope. The length of the hinge is crucial to form the immunological synapse,
where long hinge allows access to cell membrane proximal epitopes such as
carcinoembryonic antigen (CEA), neural cell adhesion molecule (NCAM), while shorter
hinge regions are used to target cell membrane distal epitopes like CD22 [183-186].
Human IgG hinge contains CH2-CH3 domain and can bind to Fc gamma receptor
(FcγR) on myeloid cell population thereby resulting in off-target activation, off-tumor
localization and poor tumor engraftment [187-189]. Point mutations can abrogate such
binding and have demonstrated enhanced CAR T-cell engraftment in the tumor with
improved anti-tumor activity in in vivo models [184, 187, 190]. Recently, CD28 and CD8α
hinge regions have been incorporated into CAR that bypasses FcγR binding as seen in
CD19 targeted CAR such as Yescarta and Kymriah respectively [191, 192].
The transmembrane (TM) domain anchors the CAR molecule in the T-cell
membrane and is the least characterized domain of the CAR. Most frequently used TM
are ones from CD3, CD28 [193]. But recently, evidences suggest that it can modulate
CAR T-cell activity. We lack in-depth knowledge of CAR signaling, but if CARs are to
act as TCRs, TM domain plays an essential role in CAR dimerization and relaying the
CAR-T signals. One study reported that specific regions on CD3 TM domains are
essential for dimerization and incorporation into endogenous TCR cluster [194]. A recent
study showed that ICOS TM is essential for enhanced CAR T-cell functionality,
persistence and anti-tumor activity when ICOS intracellular (IC) domain was
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incorporated into the CAR [195]. In conclusion, the choice of TM domain can influence
the CAR expression, stability and proper CAR T-cell signaling.
CARs incorporating only CD3 intracellular domains targeting Neu/Her-2 and 2,4,6
Trinitrophenol (TNP) showed success in mice models [196-198]. However, when tested
in clinical trials to treat renal cell carcinoma and ovarian cancer, they failed to both
persist in the body as well as control tumor [199, 200]. For optimal T cell activity and
persistence, costimulatory support is also essential. Thus, substantial efforts have been
made to incorporate and study the effect of a single co-stimulatory molecules
intracellular domain along with CD3ζ domain in the CAR. Such CARs were termed as
second generation and enhanced T cell proliferation, persistence as well as
demonstrated better tumor control (Figure 4) [201, 202]. CD28 costimulatory intracellular
domain was the first to be incorporated in a CD19 targeted CAR and showed enhanced
T-cell proliferation but did not impart a persistence advantage when compared to CD19
CAR without CD28 domain in mice leukemia models [203-205]. 4-1BB is another costimulatory domain that has been studied extensively in the CAR setting. Clinical trials
comparing CARs incorporating either CD28 or 4-1BB intracellular domains reported
similar response rates in patients with hematologic malignancies. However, CD28 CARs
were typically undetectable beyond 3 months while 4-1BB CARs could persist for
several years [206, 207]. Studies indicated that CD28 signaling imparts T cell with
enhanced proliferation, activation, glycolysis and effector functions, but shortens T cell
persistence [114, 115, 195, 208]. On the contrary, 4-1BB signaling results in increased
mitochondrial biogenesis and oxidative metabolism with slower gain of T cell effector
functions, but longer T cell persistence [114, 115, 195, 208]. Such differences in T cell
phenotype demonstrated that the choice of costimulatory domain plays a substantial
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role in both the T cell effector function, persistence and tumor control. Ultimately, this
therapy was approved by FDA for treating Acute Lymphocytic Leukemia (ALL) in young
adults (Tisaenlecleucel ~70-90% CRs) and B cell lymphomas (Axicabtagene clioleucel
~55% CRs) [209, 210].
Buoyed by this success, additional co-stimulatory and cytokine domains were
incorporated in the CAR molecules (Third generation CARs, Figure 4) that further
enhanced cellular function, proliferation and persistence [211]. The third generation
CARs exhibited superior tumor control when compared to second generation CARs in
CD38 targeted CAR when using low affinity ScFv regions [212]. Optimal T-cell growth
and persistence requires a TCR stimulation (signal 1), co-stimulation (signal 2) and
cytokine support (signal 3). Recent CARs incorporating all the three signals further
enhanced the anti-tumor effects of the CAR as opposed to a second generation that
could only provide signal 1 and 2 [213].
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Figure 4: Different generations of Chimeric Antigen Receptors
The four generation of CARs representing advances in the CAR Therapy field. Each
generation of CAR molecule consists of Single-chain variable fragment (ScFv), attached
to the transmembrane domain (TM) via a hinge/spacer link and aCD3ζ domain. The first
generation of CAR molecules lacked a co-stimulatory domain, second generation had
one while third generation consists of two disparate co-stimulatory domains. The fourth
generation consists of costimulatory domain in tandem with gene coding a cytokine under
the expression of NFAT. Figure adapted from Aaron J Smith and used with approval from
Copyright Clearance Center License number 211106-001748.

Historically, the first demonstration of clinical efficacy for CAR T cell therapy
occurred in the treatment of B-cell malignancies with CD19 targeting CARs. This
treatment leads to depletion of the normal B cells since they express CD19 as well, but
the lack of normal B cells can be managed by Immunoglobulin infusions [214, 215].
However, a more life-threatening side effect is the cytokine release syndrome (CRS),
that results from rapid immune activation of CAR-T cells causing high fever, hypotension
and potential multi-organ failure [216]. IL-6 Receptor antagonist (Tocilizumab) and
corticosteroids are the standard of care for treating CRS [216]. A fraction of patients
being treated with CD19 CAR relapse with tumors displaying antigen loss (CD19). The
targeting of CD20 and CD22 is currently being explored to treat such relapses [217219]. To overcome a single antigen loss, current efforts are focused on targeting dual
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antigens such as CD19 and CD20 in a tandem CARs (TanCARs) approach. Such a
TanCAR demonstrated promising results with an overall 79% response rate and 71%
patients having CRs in a small study of 28 patients [220].
Riding on the success in blood cancer, CAR-T approach was introduced to treat
solid tumors. Preclinical work of an EGFRvIII targeting CAR showed promise in
glioblastoma xenograft models but yielded poor results in patients with only 1/10
reaching stable disease at 18 months [221-223]. This can be attributed to multiple
reasons. Unlike B-cell malignancies, there is considerable heterogeneity in solid cancers
in terms of expression of the targeted antigen [224]. Secondly, the immune pressure
can result in antigen loss as reported in CD19 CAR targeted patients [224]. Thirdly, the
TME possesses a significant barrier for T-cell trafficking and can potentially suppress
the infiltrating CAR T cells [211, 224]. Several new approaches are currently being
developed to overcome these obstacles posed by solid cancer and with the advances
in synthetic biology, significant advances have been reported to enhance T cell
activation and persistence, tumor infiltration, and to mitigate CAR associated toxicities,
overcome TME immunosuppression and address tumor escape [225]. In solid tumors
as well as blood cancer, one of the chief limitations of CAR therapy is tumor escape due
to loss of antigens [218]. To overcome this, new CARs have been developed that targets
multiple proteins on the cancer cell. Some of them are dual CAR co-expressing two
disparate ScFv, a Tandem CAR that expresses two different ScFv in a single CAR
molecule and finally a Looped Tandem CAR that are in series or as a looped structure
[224, 226, 227]. The biggest concern in such multi-targeting CARs is the increased risk
of toxicity and ongoing clinical trials are currently evaluating this [228]. In order to
minimize toxicities, novel strategies have been employed such as combinatorial
31

approaches where T cells are engineered to co-express two CARs each targeting a
different antigen and each providing one portion of T cell signaling, one providing signal
1 (CD3ζ) while other providing costimulation or signal 2 [229]. Another approach to
control CAR activation is through dimerization using a small molecule [230]. The
magnitude and duration of activation depends on the drug dosage that can be controlled
[230]. The latest approach involves the synthetic Notch system where activation of the
first receptor induces the expression of a second CAR molecule that ultimately induces
T cell activation upon recognizing the antigen [231]. However, this approach suffers from
the same drawback of tumor escape where the tumor loses the expression of the first
antigen [231]. A novel strategy that concomitantly mitigates antigen escape and toxicity
is through universal CARs. Here, antibodies recognizing different tumor antigens are
tagged with the same “switch” that can be either a short peptide, leucine zipper or
fluorescein isothiocyanate (FITC) [232-235]. Now a CAR that recognizes this switch
instead of a tumor antigen will activate the CAR T-cell and lyse the tumor cells marked
with any of the targeted antigens [232-235]. To rescue the CAR-T cells from TME
immunosuppression and increase its cytotoxic potential, CAR-T cells were further
modified to express “armor” proteins. Such armor proteins are either cell surface or
immunomodulatory molecules that can enhance T cell functions and/or favorably
module the TME. For instance, CAR-T cells expressing TGFβ Dominant negative
Receptor (TGFβDNRII), CD40 Ligand or cytokines such as IL-12, IL-15 can foster T cell
function, control infiltration of other endogenous immune cell fractions and remodel the
immune milieu of the tumor [236-240]. Such a system represents the fourth generation
of CAR, also called T cells Redirected for Universal Cytokine Killing (TRUCKs) and is
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rapidly progressing because they can target both an antigen and secrete proinflammatory cytokines to alter the TME (Figure 4) [241].
Usually for CAR therapy, T cells isolated from PBMCs (naïve T cells) are
engineered and infused to the patients. A recent study demonstrated the feasibility of
transducing Her2 targeting CAR in TIL (effector T cells) [242]. An advantage of this
system is that it enhances the recognition of the tumor cells as the infused CAR-TIL can
recognize the tumor through its cognate TCR as well as the Her2 CAR [242]. Another
approach that has been recently used is to genetically modify T-cells with CARs against
soluble factors such as TGFβ, an immunosuppressant abundantly present in the TME,
and changing its signaling to amplify T-cell activation [243]. Developments in synthetic
biology have led to exciting advancements in CAR therapies, with enhanced anti-tumor
efficacy and improved safety.

1.4: Improvement of TIL-based Adoptive Cell Therapy using genetic engineering
TIL-ACT is often the last line of treatment and active research is being pursued
to study the mechanisms of resistance and tumor escape from TIL-ACT. Genetic
perturbations of TIL are currently being explored to overcome the shortcomings of TILtherapy. Studies currently focus on increasing TIL persistence in vivo, rescuing TIL from
TME based immunosuppression and enhancing TIL trafficking and potency. Seminal
study demonstrated constitutive expression of IL-2 in TIL resulted in enhanced
persistence without exogenous IL-2 in vitro [244, 245]. IL-2 is administered to patients
after TIL infusion for TIL persistence and is responsible for toxicities associated with TILACT therapy [37, 38]. Infusing patients with TIL expressing IL-2 would thus alleviate
administration of exogenous IL-2, however there was no improvement in TIL persistence
33

and only 1/7 patient responded [245]. In another study, TIL were genetically engineered
to produce IL-12 through NFAT promoter and induce IL-12 secretion following TCR
engagement, when the TIL recognizes its cognate antigen [246]. However, the TIL still
did not persist longer and had short lived responses accompanied with IL-12 associated
toxicity, although the ORR was a staggering 63% (10/16) in patients receiving low TIL
dose (0.3 – 3 billion TIL) [246].The other avenue that was pursued was to increase the
trafficking of TIL to the tumor through incorporation of chemokine receptors. Pmel T cells
expressing CXCR2 chemokine receptor enhanced their trafficking to the tumor following
tumor secreted CXCL1 and CXCL8 in a preclinical mouse study, which has led to an
ongoing clinical trial [247-249]. Another method to improve TIL function is to either
reduce T cell exhaustion or rescue them from TME immunosuppression. One of the first
developments in this regard was genetically modifying T cells to express a truncated
receptor for TGFβ acting as a TGFβ Dominant Negative Receptor II (TGFβDNRII) that
binds to TGFβ but does not relay downstream signaling [250, 251]. TGFβDNRII is
currently being tested to treat ICI refractory patients here at MDACC. Similarly, FASDNR demonstrated enhanced anti-tumor activity in murine models through the rescuing
of FASL mediated cell death [252]. Genetically disrupting immune checkpoint inhibitors
such as PD-1 makes TIL resistant to exhaustion, while enhancing their persistence and
tumor control in murine model [253].
Another advancement was brought about with the construction of the switch
receptors, that convert an immunosuppressive cell signal to one that is beneficial for the
T-cell. For instance, IL4/IL7 switch receptor consists of IL4 ectodomain fused to IL7
endodomain

[254].

This

IL4/IL7

switch

receptor

binds

and

converts

IL4

immunosuppressive signal to that of pro-survival IL7 signaling [254]. Similar switch
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receptors of FAS/4-1BB, PD-1/CD28, TGFβ/4-1BB have been reported in the literature
that converts an inhibitory/suppressive signal to a positive one for the T cells [255-257].
Recently, Roth et al developed pooled a high throughput knockin screening
methodology (POKI-seq) to test such synthetic/Fusion/Dominant negative receptors in
T cells and assess their fitness in vitro and in vivo in a comprehensive manner [258].
Interestingly, the most potent of their receptor was TGFβ/4-1BB synthetic fusion protein.
With immune checkpoint inhibitors becoming the standard of care in many cancers, it
has vastly changed the landscape of the TIL therapy. TIL-ACT is often the last line of
treatment and with multiple cancers becoming refractory to ICIs, it has become more
important now than ever to develop the next generation of ACTs. Well established
protocols are already in place to engineer and expand TIL for ACT in clinical settings
and will further facilitate adoption of genetically modified TIL-ACT products for patient
care worldwide [259].
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1.5: Hypothesis and Specific Aims
Tumor-infiltrating Lymphocytes (TIL) are highly selected anti-tumor T cells that
can be expanded from freshly resected tumor tissue and reinfused to the same patient
through adoptive cell therapy (ACT) as an anti-tumor therapeutic modality. Success of
TIL-ACT depends on 1] Generating a TIL product with high anti-tumor specificity and 2]
Infusing TIL that are fit to thrive and perform anti-tumor activity after re-infusion. In
general, the TIL attributes that have been associated with clinical response in Metastatic
Melanoma (MM) are the infusion of a large number of CD3+CD8+ T cells and the ability
of the TIL to engraft and persist after infusion [148, 162, 260]. Additionally, TIL are a
very heterogenous T-cell population enriched for anti-tumor activity but clonally
expanded TIL infiltrating melanoma have a high propensity to recognize mutations found
in the tumor [261]. The traditional TIL expansion method with high dose IL-2 resulted in
drastic clonality changes and loss of top TIL clones found in the tumor [262]. For these
reasons, I rationalized that an optimal method that can produce a large number of
CD3+CD8+ TIL while preserving the TIL repertoire is key, since the success of TIL
therapy is in part based on the ability of CD8+TIL to recognize an array of different tumor
antigens to avoid immune-escape.
Infused TIL can migrate back to the tumor, but long-term persistence and efficient
sustained tumor killing are essential to eradicate tumor. Multiple solid cancers create a
hostile tumor microenvironment (TME) for optimal T-cell persistence through a host of
mechanisms [263, 264]. One such mechanism is TGFβ, a pleiotropic cytokine secreted
by the majority of solid tumors that has been shown to suppress TIL function, limit their
infiltration in to the tumor and is associated with resistance to immunotherapy [265-268].
Previous work from our lab has shown that the adoptive transfer of TGFβ dominant
negative receptor (TGFβDNRII - truncated form of TGFβRII that does not relay
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downstream signaling) engineered TIL showed durable responses in heavily pretreated
immune-checkpoint refractory melanoma patients in an early phase clinical trial.
Additionally, TIL can face a deficit of essential co-stimulatory and cytokine growth
signaling in the TME, which may limit their effector function in vivo. I reasoned that
another avenue to improve T-cell function is to secure optimal activation signals in the
TME. I hypothesize that TIL engineered to express a TGFβ-chimeric antigen receptor
(TGFβ-CAR), where a TGFβ antibody is linked to intracellular domains conducing
costimulatory and cytokine signals for T cells, would not only act to block TGFβ signal
(mimicking TGFβDNRII), but would convert it to both a co-stimulatory and growth signal,
bypassing the need for the presence of professional antigen-presenting cells and prosurvival cytokines at the tumor site. TGFβ-CAR TIL would further quench TGFβ from
the TME and rescue other cell fractions that have infiltrated TME and enhance tumor
eradication. Here, TGFβ-CAR is not designed to recognize a tumor antigen but to
support and enhance the natural TCR activation of the TIL, capitalizing on the multitude
of tumor antigens recognized by TIL to prevent tumor escape as opposed to the typical
single-antigen targeted CARs [269, 270]. My central hypothesis is that efficiency of TILACT for solid cancer can be improved by optimal culture methods generating a TIL
product with enhanced tumor specificity and by genetically modifying the TIL to utilize
the immunosuppressive TGFβ to enhance TIL fitness resulting in enhanced persistence
and potency.
Aim 1:- Differential impact of TIL propagation methods on T-cell repertoire in Nonsmall cell lung cancer.
Aim 2:- Transforming immunosuppressive TGFβ signaling to a growth signal
through engineering of a TGFβ-Chimeric Antigen Receptor.
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The long-term goal of these innovative approaches is to consistently generate a
TIL-ACT product with enhanced tumor specificity. Genetically modifying these tumor
specific TIL with TGFβ-CAR will not only render them resistant to TGFβ and enhance
their potency, but also quench TGFβ’s immunosuppressive effect in the TME, thus
protecting other cell fractions and preventing tumor escape to achieve a potent antitumor
immunity in solid tumor.

Figure 5: Schematic representing Adoptive TIL Therapy and the Specific Aims
A patient undergoes a tumor resection and the minced tumor fragments are put in culture
to propagate TIL in Aim 1 [Blue Box]. Combined IL-2, agonistic CD3 and 4-1BB
stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumorinfiltrating lymphocytes. This enhanced tumor specific TIL are then genetically modified
to express TGF-β CAR to convert an immunosuppressive signaling to a potent costimulatory signaling for the transduced TIL in Aim 2 [Red Box]. Exploiting
Immunosuppressive cytokine TGFβ to enhance anti-tumor TIL function in solid cancers.
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Chapter 2 : Methods
Patients and Study Design
This study was performed on NSCLC tumor tissue resected from 16 patients
enrolled, following informed consent, in the ImmunogenomiC prOfiling of early-stage
NSCLC (ICON) project. This study was approved by the University of Texas MD
Anderson Cancer Center’s Institutional Review Board. Clinicopathological features of
patients are tabulated in Table 1.
Table 1 : Patient Clincopathological Characteristics
Patient

Expansion
Success

Age

Sex

Smoking
History

Histology

Treatment
prior to
surgery

pStage
(AJCC 7)

Survival

1

Y

61

M

Former
Smoker

SCC

None

1

Alive

2

N

73

F

Former
Smoker

SCC

Chemo

0

Alive

3

N

75

F

Former
Smoker

Adeno

Chemo

3

Alive

4

Y

74

F

Former
Smoker

Adeno

None

1

Alive

5

N

74

M

Former
Smoker

SCC

None

2

Dead

6

Y

70

F

Former
Smoker

SCC

None

3

Dead

7

Y

83

M

Former
Smoker

SCC

None

3

Alive

8

N

74

M

Former
Smoker

Adeno

None

1

Alive

9

Y

66

M

Former
Smoker

SCC

None

2

Alive

10

Y

76

M

Former
Smoker

Adeno

None

2

Alive

11

N

74

F

Former
Smoker

Adeno

Chemo

1

Alive

12

N

69

M

Former
Smoker

Adeno

Chemo

0

Alive

13

Y

72

F

Former
Smoker

Adeno

None

3

Alive

14

Y

74

M

Former
Smoker

Adeno

None

2

Alive

15

Y

58

M

Former
Smoker

Adeno

Chemo

3

Alive

16

Y

60

M

Former
Smoker

Large Cell

Chemo

3

Alive
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Table 2 : HLA Typing of Patients
Patient 1
Patient 4
Patient 6
Patient 7
Patient 9
Patient 10
Patient 14
Patient 15

HLA-A
A*01:01:01G,A*11:01P
A*34:04,A*30:01:01
A*33:03:01,A*02:01:01
A*25:01:06,A*29:01:01
A*01:01:01,A*01:01:03
A*03:01,A*02:01
A*03:01:01,A*24:02:01
A*01:01:01,A*01:01:03

HLA-B
B*07:02:01G,B*57:01P
B*35:05:01,B*42:02
B*15:16:01,B*44:02:01
B*07:05,B*08:01
B*08:01:01,B*08:01:01
B*44:02:01,B*40:01:02
B*08:01:01,B*15:01:01
B*44:03:01,B*44:03:01

HLA-C
C*07:02:01G,C*06:02P
C*04:01,C*17:01
C*14:02,C*14:02:01
C*07:01:01,C*15:05:02
C*07:01:01,C*07:01:01
C*05:01,C*05:01:01
C*07:02,C*03:04
C*07:02:01,C*16:01:01

Reagents
The fully human purified IgG4 monoclonal agonistic antibody (mAb) against
human 4-1BB (Urelumab, 663513; Lot 6A20377) was kindly provided by Bristol Myers
Squibb (BMS, New York, NY, USA) through a Materials Transfer Agreement. Human
recombinant IL-2 (ProleukinTM) was generously provided by Clinigen Inc, (formerly
known as Prometheus Therapeutics and Diagnostics) (Yardley, PA, USA).

TIL isolation and expansion from NSCLC tissue
TIL isolation and initial (pre-rapid expansion protocol, pre-REP) expansion from
patients’ tumor samples was executed using two different methods referred to as TIL
1.0 and TIL 3.0. For each tumor sample received TIL were expanded with both methods
in parallel (Figure 1A). TIL 1.0 was performed as previously described [271]. Briefly, the
tumor samples were cut into 1-3 mm3 fragments and placed in culture in 24 well plates
(1 fragment/well) in TIL complete growth media [TIL-CM: RPMI-1640 (Thermo Fisher
Scientific, Waltham, MA, USA) with GlutaMax (Gibco/Invitrogen. Grand Island, NY,
USA),

1x

Pen-Strep

(Gibco/Invitrogen),

10

(Gibco/Invitrogen),
mMol

HEPES

50

µmol/L

(Gibco/Invitrogen),
40

2-mercaptoethanol
1

mmol/L

pyruvate

(Gibco/Invitrogen) and 10% AB Human Serum (Gemini-Bioproducts, West Sacramento,
CA, USA)] supplemented with 6000 IU/mL of IL-2. Half media changes were performed
every 3-4 days with fresh TIL-CM supplemented with 6000 IU/mL of IL-2. TIL were split
into fresh wells as the cultures became confluent and expanded for a maximum period
of 5 weeks. TIL 3.0 was done as previously described [108]. Briefly, five 1-3 mm3 tumor
fragments were put in culture in a G-Rex 10 flask (Wilson Wolf Manufacturing, New
Brighton, MN, USA) in 20 mL TIL-CM supplemented with 6000 IU/mL IL-2, 10 µg/mL 41BB mAB (Urelumab, BMS, New York, NY, USA) and 30 ng/mL anti-CD3 (OKT3 clone
– Miltenyi Biotec, Bergisch Gladbach, Germany). The 4-1BB (Urelumab) antibody used
in this study is clinical grade and has been successfully integrated in the clinical
production here at MDACC (NCT00338377 and NCT03610490). Half media changes
were performed every 3-4 days with fresh TIL-CM supplemented with 6000 IU/ml of IL2 for up to 21 days. The benchmark for successful TIL 1.0 culture was established based
on a scaled down threshold used in our clinical protocol for MM TIL expansion (≥40 x10 6
cells for initially ≥20 tumor fragments). For TIL 3.0, the benchmark for success was kept
as is (≥40 x106 cells, for initially 5 tumor fragments) [108, 271]. Cell counts was
performed manually using trypan blue (Gibco/Invitrogen), and successful cultures were
cryopreserved in FBS (Gemini-Bioproducts) supplemented with 10% DMSO (Thermo
Fisher Scientific) using Nalgene’s Mister Frosties (Millipore Sigma, St-Louis, MO, USA).
For the second phase of expansion (REP), cryopreserved TIL from the pre-REP
cultures were thawed, rested for 2 days and propagated using a modified REP
previously described (Forget M et al, 2014 Journal of immunotherapy). Briefly on Day 0,
5 x105 TIL were seeded with 100x106 irradiated allogenic pooled PBMC cells (1 TIL:200
PBMC cell ratio) in a GREX-10M along with 300 ng/mL of anti-CD3 (OKT3 clone) and
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6000 IU/mL of IL-2 in 40 mL of REP-CM [50% TIL-CM and 50% AIM V (Thermo Fisher
Scientific)]. On Day 5, 20 mL of REP-CM supplemented with 6000 IU/mL IL-2 was
added. Cells concentration was determined on Day 7 and TIL were subculture. Each
flask was top at 100mL with Aim V supplemented with 6000 IU/mL IL-2. 3000 IU/mL of
IL-2 was added again on Day 9 and Day 11. On Day 14, cell count and viability were
performed using Trypan Blue.

Flow Cytometry (phenotype and functional assessment)
Expanded TIL were first washed in FACS Wash Buffer (Dulbecco’s Phosphate
Buffered Saline 1X (PBS, Thermo Fisher Scientific) with 1% Bovine Serum Albumin
(Millipore Sigma). Surface FC receptors were blocked for 10 min at room temperature
using goat serum (Sigma) diluted in FACS Wash Buffer (5%) before proceeding with a
surface staining on ice (100 µL per reaction) for 30 mins. Cell surface expression
assessment for this study was done using fluorochrome-conjugated antibodies against
CD3 FITC (SK7), CD4 PerCP-Cy5.5 (RPA-T4), CD4 BUV496 (SK3), CD28 PE-Cy7
(CD28.2), CD8 PB (RPA-T8) (all BD Bioscience, San Jose, CA, USA), LAG3 PE
(3DS223H) (Life Technologies Carlsbad, CA), PD-1 PerCP-Cy5.5 (EH12.2H7), CD27
APC (M-T271),CD8 APC-Cy7 (SK1) (Biolegend,San Diego, California, USA).Aqua or
Yellow Live/Dead viability stain (Thermo Fisher Scientific) was used to exclude dead
cells from analysis. Stained cells were fixed with 1% paraformaldehyde (Electron
Microscope Sciences Hatfield, PA, USA) solution for 20 mins at room temperature.
For functional assessment fresh post-REP TIL were washed in PBS and rested
O/N without IL-2 in TIL-CM or if cryopreserved, thawed and rested O/N in the presence
42

of 100 IU/mL of IL-2 followed by a pre-assessment incubation of 6 hours without IL-2.
Rested TIL (0.5e6) were incubated for 6 hours at 37°C with the CD107a (H4A3) flow
cytometry antibody (BD Bioscience) in addition to PMA/Ionomycin or TIL-CM alone
(unstimulated control) in a 96wp. 1 hour into the incubation, the GolgiStop Monensin
(BD Bioscience) was added. Post-incubation, cells were harvested and a surface
staining was performed as describe above using the CD3 FITC (SK7), CD4 PerCPCy5.5 (RPA-T4) and CD8 PB (RPA-T8). Cells were then fixed and permeabilized for
intracellular staining using the BD Cytofix/Cytoperm (BD Bioscience). Cells were then
blocked once again using goat serum and intracellularly-stained fluorochromeconjugated antibodies against IFNγ PE-Cy7 (B27) and TNFα APC (Mab11) (BD
Bioscience).
Samples were acquired using the BD FACS Canto II or DB LSRFortessa and
analyzed using FlowJo Software (Tree Star, Inc.). For surface stain analysis, gating was
performed using fluorescence minus one (FMO) when required. For functional
assessment by flow cytometry, gating was performed by using the unstimulated
condition.
DNA extraction and TCR sequencing
DNA was extracted from freshly resected tumor samples (post pathology quality
control) and expanded pre-REP and post-REP TIL for TCR sequencing on bulk TIL
populations. For fresh tissue, DNA was extracted utilizing the Qiagen QIAamp DNA Mini
kit (Qiagen, Germantown, MD, USA) as per manufacturer’s instructions. For expanded
TIL DNA was extracted using DNeasy Blood and Tissue Kit as per manufacturer’s
instructions. Sequencing of the CDR3 regions of human TCR-β was performed using
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the immunoSEQ Assay (Adaptive Biotechnologies, Seattle, WA, USA) with T cell
genomic DNA supplied by the manufacturer as positive control and 1x TE Buffer as
negative control. Briefly, T-cell clonality in each sample was measured by 1- Pielou’s
evenness [272]. T-cell diversity was defined by the number of unique nucleotide
rearrangements within a sample by richness. Frequencies of unique nucleotide
rearrangements were compared between samples to identify differentially abundant
clones. Parameters were as follows: min Total= 1, productive Only= True, all
sequences= True alpha = 0.05, count = nucleotide. Overall repertoire overlap between
samples was measured using the Morisita Overlap and Jaccard indices. Morisita overlap
values were calculated using the Horn modification to restrict the range of possible
values to between zero and one. Jaccard index values were calculated by dividing the
number of shared unique nucleotide sequences by the sum of all unique nucleotide
sequences between two samples.
Clustering TCR with GLIPH2 and Putative Tumor TCRs
In order to identify and cluster convergent complementarity-determining region 3
(CDR3) sequences that likely target the same antigen, we utilized the GLIPH2 (grouping
of lymphocyte interaction by paratope hotspots) algorithm [273]. GLIPH2 was
implemented using the OSX executable irtools v0.01 with default parameters without
HLA input. Significant clusters were considered as those with at least 3 unique TCR
sequences and significant V-gene enrichment (Fisher’s exact test p< 0.05). Curated
publicly available TCR sequences with known antigen specificity were utilized to identify
viral-specific motifs [274]. To identify putative tumor-specific TCR, we excluded all motifs
with known viral targets, as well as all motifs occurring at a frequency greater than 1x10-
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4

in normal adjacent tissue from any patient in the study. Cluster visualization was

performed in Cytoscape v3.8.2.

Cloning of chimeric TGFβDNRII and TGFβ-CAR constructs, viral production and
TIL Transduction
All the TGFβDNRII and CAR constructs as shown in Table 2 and Table 3 were
cloned in the pMSGV1 vector. The sequence was verified using sanger sequencing.
These plasmids were transfected in Phoenix Eco cells using lipofectamine and media
changed after 6 hrs. Viral sup was collected after 48 hrs and was used to transduce
PG13 with 8 µg/ml of polybrene (Millipore). Transduced PG13 were stained with either
TGFβDNRII or TGFβ-CAR tag -APC antibodies and enriched using anti-APC
microbeads (Miltenyi Biotec, Auburn, CA, USA). Viral sup was then collected from this
purified PG13 transduced cells and was used to transduce TIL as per Forget M et al
[259]. Briefly, pre-REP TIL were thawed and rested for 2 days and activated with OKT3
for 1 day. Following day (day of transduction), viral sup collected from PG13 cells were
centrifuged on retronectin coated plates for 2 hrs. Following centrifugation, viral sup was
aspirated and activated TIL were added to the plates and centrifuged for 10 mins. Next
day, 0.5e6 transduced TIL were collected and a REP was performed as described in our
previous section without OKT3 activation.
Table 3: Amino Acid sequences for TGFβDNRII Constructs
Signal Peptide
GM-CSF Signal peptide

MLLLVTSLLLCELPHPAFLLIP

Transmembrane Domains
FWVLVVVGGVLACYSLLVTVAFIIFWV
CD28 TM
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Important Components of the TGFβRII
Signaling Peptide
MGRGLLRGLWPLHIVLWTRIAS
Transmembrane
VTGISLLPPLGVAISVIIIFY
Domain
TWETGKTRKLMEFSEHCAIIL
Recycling Motif
Furin-P2A-GFP

RAKRSGSGATNFSLLKQAGDVEENPGPMVSKGEELFTGVVPILVELDGDV
NGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFS
RYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNR
IELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIE
DGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLE
FVTAAGITLGMDELYK

WT TGFβRII

MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFC
DVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHD
FILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQVT
GISLLPPLGVAISVIIIFYCYRVNRQQKLSSTWETGKTRKLMEFSEHCAIILEDDRSDIS
STCANNINHNTELLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEEYAS
WKTEKDIFSDINLKHENILQFLTAEERKTELGKQYWLITAFHAKGNLQEYLTRHVIS
WEDLRKLGSSLARGIAHLHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFG
LSLRLDPTLSVDDLANSGQVGTARYMAPEVLESRMNLENVESFKQTDVYSMALVL
WEMTSRCNAVGEVKDYEPPFGSKVREHPCVESMKDNVLRDRGRPEIPSFWLNH
QGIQMVCETLTECWDHDPEARLTAQCVAERFSELEHLDRLSGRSCSEEKIPEDGSL
NTTK

Current TGFβDNRII

MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFC
DVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHD
FILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQVT
GISLLPPLGVAISVIIIFYCYRVNRQQKLSS

Current TGFβDNRII-GFP

MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFC
DVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHD
FILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQVT
GISLLPPLGVAISVIIIFYCYRVNRQQKLSSRAKRSGSGATNFSLLKQAGDVEENP
GPMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFI
CTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERT
IFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNS
HNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPD
NHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK

CB1

MLLLVTSLLLCELPHPAFLLIPTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVR
FSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILE
DAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQSKRSRG
GHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSCYRVNRQQKLSSRAKRSGS
GATNFSLLKQAGDVEENPGPMVSKGEELFTGVVPILVELDGDVNGHKFSV
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SGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMK
QHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGID
FKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLA
DHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGI
TLGMDELYK

CB2

MLLLVTSLLLCELPHPAFLLIPTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVR
FSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILE
DAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQSKRSRG
GHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSCYRVNRQQKLSSTWETGKT
RKLMEFSEHCAIILRAKRSGSGATNFSLLKQAGDVEENPGPMVSKGEELFTG
VVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTL
VTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRA
EVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNG
IKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKD
PNEKRDHMVLLEFVTAAGITLGMDELYK

Table 4: Amino Acid sequences for TGFβ-CAR Constructs
Signal Peptide
GM-CSF Signal peptide
Murine
Peptide

IgGk

Tag
ScFv
VH
VL

Linker
Whitlow Linker
(G4S)3 Linker
Hinge Options
12 aa short Hinge
CD8a Stalk
IgG Stalk

MLLLVTSLLLCELPHPAFLLIP

Signal METDTLLLWVLLLWVPGSTG

DYKDDDDK

QVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMGG
VIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCALPR
AFVLDAMDYWGQGTLVTVSS
ETVLTQSPGTLSLSPGERATLSCRASQSLGSSYLAWYQQKPGQAPRLLIY
GASSRAPGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYADSPITFG
QGTRLEIK

GSTSGSGKPGSGEGSTKG
GGGGSGGGGSGGGGS

ESKYGPPCPPCP
TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD
APEFLGGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYV
DGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLP
SSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAV
EWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMH
EALHNHYTQKSLSLSLGKM
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IgG* Stalk

APPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDG
VEVHNAKTKPREEQFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSS
IEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEW
ESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA
LHNHYTQKSLSLSLGKM

Transmembrane Domains
FWLPIGCAAFVVVCILGCILI
ICOS TM
FWVLVVVGGVLACYSLLVTVAFIIFWV
CD28 TM
Intracellular Domains
ICOS IC
4-1BB IC

ΔIL-2Rβ
Furin-P2A-GFP

CWLTKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL
KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
NCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDVQKWLSSPFPSSSFSP
GGLAPEISPLEVLERDKVTQLLPLNTDAYLSLQELQGQDPTHLV
RAKRSGSGATNFSLLKQAGDVEENPGPMVSKGEELFTGVVPILVELDGDV
NGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFS
RYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNR
IELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIE
DGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLE
FVTAAGITLGMDELYK

TGFβ-CAR Tag 12 amino MLLLVTSLLLCELPHPAFLLIPDYKDDDDKQVQLVQSGAEVKKPGSSVKV
SCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTI
acid Stalk
TADESTSTTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQGTLVTVSS
GSTSGSGKPGSGEGSTKGETVLTQSPGTLSLSPGERATLSCRASQSLGSS
YLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPE
DFAVYYCQQYADSPITFGQGTRLEIKESKYGPPCPPCPFWLPIGCAAFVV
VCILGCILICWLTKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTLKRG
RKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCELNCRNTGPWLKK
VLKCNTPDPSKFFSQLSSEHGGDVQKWLSSPFPSSSFSPGGLAPEISPLE
VLERDKVTQLLPLNTDAYLSLQELQGQDPTHLVRAKRSGSGATNFSLLKQ
AGDVEENPGPMVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATY
GKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMP
EGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGH
KLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIG
DGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK

TGFβ-CAR Tag IgG Stalk

MLLLVTSLLLCELPHPAFLLIPDYKDDDDKQVQLVQSGAEVKKPGSSVKV
SCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTI
TADESTSTTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQGTLVTVSS
GSTSGSGKPGSGEGSTKGETVLTQSPGTLSLSPGERATLSCRASQSLGSS
YLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPE
DFAVYYCQQYADSPITFGQGTRLEIKESKYGPPCPPCPAPEFLGGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKP
REEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG
QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY
KTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSL
SLSLGKMFWLPIGCAAFVVVCILGCILICWLTKKKYSSSVHDPNGEYMFM
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RAVNTAKKSRLTDVTLKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPE
EEEGGCELNCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDVQKWLSSP
FPSSSFSPGGLAPEISPLEVLERDKVTQLLPLNTDAYLSLQELQGQDPTH
LVRAKRSGSGATNFSLLKQAGDVEENPGPMVSKGEELFTGVVPILVELDG
DVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQC
FSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLV
NRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHN
IEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVL
LEFVTAAGITLGMDELYK

TGFβ-CAR Tag CD8 Stalk
VH-VL
TGFβ-CAR Tag CD8 Stalk MLLLVTSLLLCELPHPAFLLIPDYKDDDDKETVLTQSPGTLSLSPGERAT
LSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGT
VL-VH
DFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIKGSTSGSGKPGSG
EGSTKGQVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQG
LEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVY
YCALPRAFVLDAMDYWGQGTLVTVSSTTTPAPRPPTPAPTIASQPLSLRP
EACRPAAGGAVHTRGLDFACDFWLPIGCAAFVVVCILGCILICWLTKKKY
SSSVHDPNGEYMFMRAVNTAKKSRLTDVTLKRGRKKLLYIFKQPFMRPVQ
TTQEEDGCSCRFPEEEEGGCELNCRNTGPWLKKVLKCNTPDPSKFFSQLS
SEHGGDVQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLPLNTDA
YLSLQELQGQDPTHLVRAKRSGSGATNFSLLKQAGDVEENPGPMVSKGEE
LFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNY
KTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADK
QKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSA
LSKDPNEKRDHMVLLEFVTAAGITLGMDELYK
TGFβ-CAR Tag IgG* Stalk MLLLVTSLLLCELPHPAFLLIPDYKDDDDKQVQLVQSGAEVKKPGSSVKV
SCKASGYTFSSNVISWVRQAPGQGLEWMGGVIPIVDIANYAQRFKGRVTI
VH-VL
TADESTSTTYMELSSLRSEDTAVYYCALPRAFVLDAMDYWGQGTLVTVSS
GSTSGSGKPGSGEGSTKGETVLTQSPGTLSLSPGERATLSCRASQSLGSS
YLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDFTLTISRLEPE
DFAVYYCQQYADSPITFGQGTRLEIKESKYGPPCPPCPAPPVAGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPRE
EQFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP
REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL
SLGKFWLPIGCAAFVVVCILGCILICWLTKKKYSSSVHDPNGEYMFMRAV
NTAKKSRLTDVTLKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEE
GGCELNCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDVQKWLSSPFPS
SSFSPGGLAPEISPLEVLERDKVTQLLPLNTDAYLSLQELQGQDPTHLVR
AKRSGSGATNFSLLKQAGDVEENPGPMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSR
YPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRI
ELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIED
GSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEF
VTAAGITLGMDELYK
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TGFβ-CAR Tag IgG* Stalk MLLLVTSLLLCELPHPAFLLIPDYKDDDDKETVLTQSPGTLSLSPGERAT
LSCRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGT
VL-VH
DFTLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIKGSTSGSGKPGSG
EGSTKGQVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQG
LEWMGGVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVY
YCALPRAFVLDAMDYWGQGTLVTVSSESKYGPPCPPCPAPPVAGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPRE
EQFQSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP
REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT
TPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL
SLGKFWLPIGCAAFVVVCILGCILICWLTKKKYSSSVHDPNGEYMFMRAV
NTAKKSRLTDVTLKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEE
GGCELNCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDVQKWLSSPFPS
SSFSPGGLAPEISPLEVLERDKVTQLLPLNTDAYLSLQELQGQDPTHLVR
AKRSGSGATNFSLLKQAGDVEENPGPMVSKGEELFTGVVPILVELDGDVN
GHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSR
YPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRI
ELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIED
GSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEF
VTAAGITLGMDELYK

TGFβ-CAR Control

METDTLLLWVLLLWVPGSTGDYKDDDDKETVLTQSPGTLSLSPGERATLS
CRASQSLGSSYLAWYQQKPGQAPRLLIYGASSRAPGIPDRFSGSGSGTDF
TLTISRLEPEDFAVYYCQQYADSPITFGQGTRLEIKGGGGSGGGGSGGGG
SQVQLVQSGAEVKKPGSSVKVSCKASGYTFSSNVISWVRQAPGQGLEWMG
GVIPIVDIANYAQRFKGRVTITADESTSTTYMELSSLRSEDTAVYYCALP
RAFVLDAMDYWGQGTLVTVSSAPEFLGGPSVFLFPPKPKDTLMISRTPEV
TCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVL
HQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSR
LTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGKFWVLVVVGGVLA
CYSLLVTVAFIIFWVRSKRSRGGHSDYMNMTPRRPGPTRKHYQPYAPPRD
FAAYRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPE
MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLS
TATKDTYDALHMQALPPRRAKRSGSGATNFSLLKQAGDVEENPGPMVSKG
EELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLP
VPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDG
NYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMA
DKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQ
SALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK

TGFβDNRII and TGFβ-CAR surface expression assessment pre and post TIL
activation
TIL were activated with 300 ng OKT3 for a day at 1e6/ml in TIL media. They were
then collected, washed once with PBS and processed for flow staining or other
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experiments. Resting or activated TIL Cell surface assessment for TGFβDNRII and
TGFβ-CAR surface expression, TIL were stained against TGFβRII APC (Clone 25508)
(R&D systems, Minneapolis, MN, USA), IgG Fcγ Fragment APC (Jackson Immuno
research laboratories, West Grove, PA, USA) and Anti – DYKDDDDK tag APC (L5)
(Biolegend).
SMAD2/3 and STAT5 Phosphorylation Assay in TIL upon TGFβ stimulation
For pSMAD2/3 and pSTAT5 flow functional assessment, TIL were washed in
PBS and rested O/N without IL-2 in 0.1% TIL-CM at a concentration of 0.5e6/100 µl in a
96 flat bottom plate at 37°C in an incubator. Following day, they were stimulated with
BSA (control), TGFβ (1, 2.5, 5 and 10 ng/mL) (R&D) and IL-2 (1000 IU/mL) (Clinigen)
for mentioned time points. At the end of incubation, TIL were collected and fixed with
Phosflow Lyse/Fix buffer (BD Biosciences) for 10 mins at 37 oC. Cells were washed
permeabilized with 300 ul of Phosflow Perm Buffer II (BD Biosciences) and incubated
on ice for 30 mins. They were washed twice and stained with pSMAD2/3 AF-647 (Clone
O72-670), pSTAT5 AF-647 (Clone 47/Stat5 pY694) from BD biosciences. For pSMAD
2 western blot, TIL were washed with PBS and rested for 2 hrs in the incubator.
Following resting, they were stimulated with TGFβ and at the end of their stimulation,
they were collected, washed once with ice cold PBS, and lysed with RIPA buffer along
with Halt Phosphatase and protease inhibitor (ThermoFisher). Protein content was
assayed using the BCA Assay Kit (Biorad). 25 ug of the protein was run on precast gels.
Protein bands were transferred using dry method (iblot system, Invitrogen, Carlsbad,
CA, USA). Membrane was blocked with 5% milk in TBST for 1 hr at RT. It was blotted
for TGFβRII (AF-241, R&D), Anti-phospho SMAD2 (Clone A5S, Millipore, Burlington,
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MA), Anti-SMAD2 (ab63576) and HRP-linked beta Actin (ab49900) from Abcam
(Cambridge, MA, USA).

Statistical Analysis
The majority of statistical analyses were performed using GraphPad Prism v8
(GraphPad software), Fisher’s exact test, Sign-rank test and paired t-tests were used
when appropriate.
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Chapter 3: Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve
clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating
lymphocytes
3.1: Introduction
Lung cancer is the deadliest cancer with an estimated 135,000 deaths in the USA
in 2020 alone [275]. The majority of lung cancer diagnoses (~84%) are classified as
non-small cell lung cancer (NSCLC) [275]. Current treatments elicit a limited response
with a 5-year survival rate averaging 25% for NSCLC patients and a mere 7% in patients
with metastatic disease [American cancer Society]. The success and response rates
associated with immunotherapy in the setting of metastatic melanoma (MM) have
resulted in excitement for this type of treatment in NSCLC. Similar to MM, NSCLC
exhibits a high mutational burden which correlates with favorable immunotherapy
outcomes [276, 277] particularly because these somatic mutations may give rise to
tumor neoantigens capable of triggering host T-cell responses and eliciting clinical
responses [278, 279].
Anti-programmed-death-1 (PD-1) is now the standard of care in advanced
NSCLC, demonstrating tumor regression in up to 20% of patients [280-282]. Despite
these encouraging results, the majority of patients do not respond to treatment or
eventually recur. This has prompted interest in exploring additional immunotherapeutic
interventions such as adoptive cell therapy (ACT) using tumor infiltrating-lymphocytes
(TIL). TIL-ACT has proven highly effective in MM with an overall response rate of 4050% and 10-20% of treated patients showing complete and durable long-term response
[150, 161, 162, 283, 284]. Similar to MM, tumor-reactive TIL have been reported in
NSCLC, prompting exploration of TIL-ACT in NSCLC [285, 286]. In the late 1990s, Ratto
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G et al. reported minor survival benefits after infusion of NSCLC patients with autologous
expanded TIL [168]. Since this report, TIL-ACT has substantially evolved in both
manufacturing process of the infusion product and the host pre-conditioning. These
efforts have been particularly focused in MM. The introduction of a non-myeloablative
lymphodepleting pre-treatment regimen to TIL-ACT has substantially augmented clinical
response and persistence of TIL post-transfer [287]. Culture methods to robustly expand
TIL from tumor resections have also been optimized [108, 133, 140, 288].
Numerous groups have reported successful NSCLC TIL expansion and
treatment of patients using traditional TIL culture method which involves culture of tumor
fragments in media containing high dose of IL-2 (further referred to as TIL 1.0) (Creelan
B, Nat Med 2021,PMID 34385708) [260, 289, 290]. However, contrary to TIL propagated
from MM, the majority of these studies reported expansion of a high proportion of CD4+
TIL with corresponding lower CD8+ TIL proportion. In prior work from our group and
others in MM, infusion of a higher frequency and number of CD8+ TIL was posited to
contribute to positive clinical outcomes [150, 283, 284]. To elicit expansion of a NSCLC
TIL product sharing critical attributes shown to be important for MM TIL products, we
applied a new propagation process initially developed to improve success rate, shorten
the time required for expansion and improve CD8 + TIL frequency from cutaneous and
uveal melanoma tumor specimens [108]. This method (termed TIL 3.0 since it uses three
stimulatory signals to expand TIL) capitalizes on the 3-signals required for optimal T-cell
activation [1) agonistic stimulation of CD3 (TCR engagement), 2) agonistic stimulation
of 4-1BB (co-stimulation) and 3) IL-2 (cytokine exposure)] and differs from the traditional
IL-2 expansion method relying solely on one signal. This initial stage of propagating TIL
from tumor tissue is called pre-Rapid expansion protocol (pre-REP). Streamlining the
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process of growing TIL is important but it is unclear how the process affects the TCR
repertoire in expanded TIL. Preservation of the breadth of the TCR repertoire from the
tumor tissue is deemed important as the success of TIL therapy is in part based on the
ability of TIL to recognize an array of different tumor-associated antigens (TAA) to avoid
immune-escape. Here, we demonstrate that our new TIL 3.0 propagation method at preREP stage, consistently expands a larger number of T-cell clones from the tumor tissue,
better capturing the repertoire present in the tumor, while augmenting the total yield of
TIL, in particular CD8+ TIL, in a constantly shorter time frame in comparison to the
traditional expansion method with IL-2 alone. This fast growth did not over differentiate
the TIL and showed a higher proportion of putative tumor-specific TCR compare to the
traditional IL-2 method. However, these observations did not hold true in the second
phase of expansion (REP) suggesting that a scaled-up, one phase expansion TIL 3.0
product would be more suitable for ACT in NSCLC.

3.2: Results
3.2.1 : The 3-signal TIL 3.0 method improves TIL expansion, augments CD8 + TIL
frequency and expands a more diverse T-cell repertoire
Fresh NSCLC tumors underwent TIL expansion using both the TIL 1.0 and TIL
3.0 propagation methods from the same tumor tissue as depicted in Figure 6A. As
shown in Figure 6B, TIL 3.0 greatly increased the total number of TIL grown (median of
186.3x106 vs 18.5x106, p<0.0001), enriching for CD8+ TIL (median of 86.43% vs
29.67%, p=0.001, Figure 6C left panel) while decreasing the proportion of CD4 + TIL
(median of 2.83% vs 38.83%, p=0.0082, Figure 6C right panel). TIL 3.0 also allowed for
a shorter time in culture (median of 14 days vs 27.5 days, Figure 6D). When visualizing
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the results in an x/y graph where four quadrants are formed using lines drawn from the
median (median number of days in culture for the x axis and median number of TIL for
the y axis), almost all TIL 3.0-expanded samples fell within Q2, while almost TIL 1.0
samples fell within Q4 (Figure 6D). This suggests that TIL 3.0 consistently expands TIL
in both greater number and lesser time (p<0.0001, Figure 6E). The overall success rate
of establishing NSCLC TIL cultures was 62.5% for TIL 1.0 (≥12 x106 cells) compared to
100% for TIL 3.0 (≥40 x106 cells, Figure 6F).
The voluminous and accelerated expansion of TIL brought by the TIL 3.0 culture
method prompted us to explore its impact on the T-cell repertoire. To assess the T-cell
repertoire in cultures obtained from both propagation methods, we performed next
generation sequencing of the CDR3 variable region of the T-cell receptor (TCR).
Richness, a measure of T-cell diversity, was significantly higher in TIL expanded with
TIL 3.0 when compared to TIL 1.0 (3,032 vs 1,046 clonotypes, p=0.039, Figure 6G).
Conversely, clonality was higher in TIL 1.0 (0.4 vs 0.15, p=0.0078, Figure 6H). This
demonstrates the TIL 3.0 propagation method expands a broader repertoire of
clonotypes than traditional expansion with high dose of IL-2.
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Figure 6: The novel expansion method, TIL 3.0, enriches for CD3+ and CD8+ TIL while
preserving T-cell diversity
(A) Schematic depicting TIL expansion from a single lung tumor resection. The minced tumor
fragments are put in culture to propagate TIL with either the TIL 1.0 or TIL 3.0 method. (B)
Comparison of the total TIL number expanded using the traditional culture method, TIL 1.0
(red) and the novel culture method, TIL 3.0 (blue) (paired, n=16). (C) The percentage of
CD3+CD8+ TIL (left panel) and the percentage of CD3+CD4+ TIL (right panel) (paired, n=10) in
successful TIL cultures for both expansion method. (D) Time of culture with median of total
TIL number expanded and days in culture (paired, n=16). The graph is divided in quadrants
according the median of TIL expanded vs number of days. (E) Percentage of patients in each
quadrant for TIL 1.0 and TIL 3.0 from 1D. (F) Success rate of growth for each TIL expansion
method (paired, n=16). Comparison of TCR richness (G) and clonality (H) of expanded TIL
using TIL 1.0 vs TIL 3.0 (paired, n=9). Statistical analysis was performed by paired T test (B)
and (C), a chi-square test was performed in (E) and a sign-rank test was performed in (G) and
(H).

3.2.2 : The 3-signal TIL 3.0 method improves TIL expansion, augments CD8 + TIL
frequency and expands a more diverse T-cell repertoire
Poschcke et al. have reported that TIL cultured through traditional TIL 1.0 method
undergo drastic TCR repertoire changes from the initial tumor samples both in
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melanoma and pancreatic ductal adenocarcinoma (PDAC) [291]. In fact, TIL expanded
with this method tend to lose a majority of the clonotypes found in the tumor including
clonotypes dominating the TCR repertoire in the resected tumor, leading to the
emergence of rare clonotypes in the expanded TIL product [291]. Given the difference
we observed in richness and clonality in NSCLC TIL between both expansion methods,
we next evaluated changes in the composition of the T-cell repertoire. Figure 7A show
T-cell clones shared between the tumor tissue and TIL expanded from either TIL 1.0 or
TIL 3.0. Overall, TIL 3.0 exhibited a tendency to expand more TIL clones to a frequency
comparable to their original frequency in the resected tumor. To quantitatively assess
this, we first determined the Jaccard index, which compares how many clonotypes were
shared between the freshly resected tumor and expanded TIL cultures, finding a trend
towards TIL 3.0 sharing more clones with the resected tumor (0.067 vs 0.037, p=0.07,
Figure 7B). For a more precise measure of homology, we next determined the Morisita
Overlap Index (MOI), which accounts for not only presence/absence of a given
clonotype, but also the relative abundance of clonotypes in both fresh and expanded
TIL. We found that TIL 3.0 cultures were significantly more similar to fresh TIL than TIL
1.0 cultures (0.37 vs 0.028, p=0.0007, Figure 7C). We further assessed the top 100 TIL
clones found in the resected tumor with the top 100 TIL clones of the expanded TIL
product. As shown in Figure 7D-E, the top 100 TIL 3.0-expanded clones shared a higher
number of clones within the top 100 clones in the resected tumor (mean of 31 for TIL
3.0 vs 23 for TIL 1.0, p=0.034).
It was previously shown that the top TIL clones found in MM tumors exhibit
enriched tumor specificity and could be critical to anti-tumor responses [292]. Based on
this finding, we next focused on the top 10 TIL clones found in NSCLC tumors and
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assessed both their presence and frequency in the expanded TIL product from both
culture methods. As represented in Figure 7F-H, the top 10 resected tumor T-cell clones
presented significantly higher frequencies in the TIL 3.0 than in the TIL 1.0 product
(mean of 0.16 for TIL 3.0 vs 0.036 for TIL 1.0, p<0.00001), signifying that the top ranked
TIL clones found in the tumor better maintained their ranks in the expanded TIL 3.0.
Altogether, these findings suggest that TIL 3.0 expands a NSCLC TIL product
that better recapitulates the tumor when compared to products generated with TIL 1.0.
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Figure 7: Both TIL propagation methods result in distinct TCR repertoires with TIL
3.0 maintaining a higher resemblance to tumor.
(A) Representative differential abundance plot comparing expanded T-cell repertoire in TIL
1.0 v/s tumor (left panel) and TIL 3.0 v/s tumor (right panel). Each circle represents a unique
TCR TIL clone. Circles on either axis represents clones that are exclusively present in tumor
(Y-axis) or expanded in grown TIL product (X-axis). Clones with reads greater than or equal
to one were included. The black solid line is the frequency equality line and circles adjoining
the equality line represents TCR clones that are equally expanded both in the tumor and the
grown TIL product. Blue circles represent TIL TCR clones preferentially expanded in the
grown TIL and the red circles represents TCR clones preferentially present in the tumor.
Comparison of (B) Jaccard index (paired, n=9) and (C) Morisita overlap index (paired, n=9)
between TIL 1.0 and TIL 3.0 expanded product to tumor. (D) Heatmap of proportion of top
100 TIL clones present in the tumor in TIL 1.0 and TIL 3.0 clones stratified per patient; each
vertical row represents a patient (n=9). (E) Comparison of the proportion of top 100 TIL
clones found in the tumor present in the top 100 TIL 1.0 and TIL 3.0 clones (paired, n=9).
(F) Representative plot of comparison of the productive frequency of top 10 resected tumor
T-cell clones tumor clones in grown TIL 1.0 and TIL 3.0 product. (G) Comparison of the
productive frequency of top 10 TIL clones found in the tumor and the productive clonality of
the same TIL clones in the top 10 TIL 1.0 and TIL 3.0 expansion product (paired, n=9) (H)
Representative Alluvial plot depicting the top 10 ranked TIL clones found in the tumor to
their corresponding rank in TIL 1.0 and TIL 3.0 culture method. N/A means not present in
top 10 and * means they are not present in expanded TIL product. Shaded region in each
clone represents the productive frequency (range from 0.0 – 0.2). Statistical analysis was
performed by paired T test on (B), (C), (E) and (F).
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3.2.3 : Putative tumor-specific TCR are better retained in TIL expanded with TIL
3.0
As previously mentioned, the effectiveness of TIL ACT in MM has been in part
attributed to the diversity of TAA able to be recognized by the infused TIL. Similar to the
skin, the lungs experience multiple viral infections and are likely to retain a high
proportion of memory T cells of viral antigen specificities. Recent data suggests that
NSCLC tumors are also surveyed by viral-specific memory T cells which thus should be
detected in both the tumor and the normal tissues [293-295]. In order to properly assess
which of the two TIL propagation methods was able to better expand TAA-specific TIL,
we began by clustering convergent TCR sequences with a shared motif using GLIPH2
(Grouping of Lymphocyte Interaction by Paratope Hotspots version 2), alluding to a
group of TCR able to recognize the same antigen. The TCR sequences that did not
cluster were considered unique and labeled “TCR clones” [273]. Across the 601,171
TCR sequences spanning all the patient samples (adjacent uninvolved tissue, tumor
and expanded TIL 1.0 and TIL 3.0 T cells), we identified 14,614 clusters. An example of
a single such TCR cluster is presented in Figure 8A. Identified TCR clusters contained
a mode of 3 patients per cluster and based on our prior work showing shared TCR
sequences are enriched for viral TCR, we hypothesized that many of these clusters
likely targeted viral antigens [294]. Cross referencing both individual clones and TCR
clusters with known viral-specific TCR databases revealed that TCR in clusters were
significantly enriched for known viral-specific sequences when compared to individual
TCR clones (mean of 27.46 % of cluster vs 1.114% of clone, p= 2.5 x 10-323, Figure 8B).
Finally, in order to focus our analysis on TCR that may be targeting tumor cells,
we excluded all viral-specific TCR identified (Figure 8A-B), along with all the TCR found
in the normal uninvolved tissue of any patient from analysis. An example “putative tumor61

specific TCR” representative network is shown in Figure 8C, where the repertoire of
putative TAA-specific TCR (clusters and clones) found in the initial NSCLC and the
expanded TIL from both methods can be visualized for individual patients. As observed
in the network, while clones that expand by one protocol are more likely to expand by
both protocols (p=0.00033 for Figure 8C,p=8.2x10-228

for all samples), this

corresponded to TIL 3.0 expanding 80% of TAA-specific TCR from TIL 1.0, whereas
TIL1.0 only expanded 56.5% of TAA-specific TCR from TIL 3.0 (Figure 8D), indicating
significant loss of potential T cells that could target the tumor. When looking across all
9 patients, we observed that the putative tumor-specific TCR clones/clusters found in
the baseline tumor were preserved at a significantly higher proportion in the TIL 3.0
expanded TIL compared to TIL 1.0 (median of 6% for TIL 1.0 vs median of 20.31% for
TIL 3.0, p=0.00391, Figure 8E).
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Figure 8: Putative tumor-specific TCR are better retained in TIL expanded with TIL
3.0
(A) An example a single TCR cluster which share the central S%GET motif and potentially
recognize the same antigen, as annotated by GLIPH2. Each circular pattern represents a
single patient. Circles indicate TCR motif found in uninvolved lung tissue, squares represent
NSCLC tissue, diamonds for TIL 1.0 expanded TCR and triangles indicate TIL 3.0 expanded
TCR. Grey lines connect similar TCR motifs across patients, tissue compartments and
expanded TIL products. (B) Graph representing percentage of predicted viral-specific TCR
found in TCR clusters and clones defined in (A) across all patients’ samples. (C)
Representative graph of putative tumor-specific TCR [clones (circles) and clusters
(triangles)] found in the baseline NSCLC tissue (green), TIL expanded with TIL 1.0 (red) and
TIL 3.0 (blue) from a single patient. The connecting grey lines represents the shared TCR
motif from the tumor tissue and their homologous TCR in the expanded TIL product. (D) Pie
charts depicting the proportion of TAA-specific expanded TIL found exclusively (light gray)
in TIL 1.0 expanded product (left) and in TIL 3.0 (right). The dark gray represents the
proportion of TAA-specific expanded TIL from each respective method that are found in the
product of the other expansion method. (E) Graph displaying the comparison of the retained
putative tumor-specific TCR in TIL 1.0 and TIL 3.0 expansion product across all patients
(paired, n =9).
63

3.2.4 : Characterization of the pre-REP TIL product reveals that TIL 3.0 expanded
TIL are less differentiated than their post-REP counterpart but neither are
exhausted
We next expanded pre-REP TIL generated from both methods using the same
process leading to the generation of the TIL infusion product, the REP, in order to
validate the maintenance of our previous findings at the pre-REP stage. Six matched
pairs of TIL 1.0 and TIL 3.0 were used for this validation. As presented in Figure 9A, the
final product generated with TIL 3.0 displayed an enhanced expansion potential during
the REP over post-REP TIL 1.0 culture (mean of 3364x for TIL 3.0 vs 1613x for TIL 1.0,
p=0.0035, Figure 9B). All TIL 1.0 and TIL 3.0 post-REP cultures exhibited over 90%
viability (Figure 9A). The final TIL product generated from TIL 3.0 also retained both its
enriched CD8+ TIL phenotype described at the pre-REP level (median of 88.75% vs
41.45%, p=0.0091, Figure 9C left panel) with a lower CD4+ TIL population (median of
3.595% vs 51.35%, p=0.0079, Figure 9C right panel). Altogether, TIL 3.0 consistently
expanded better than TIL 1.0 while retaining its pre-REP CD8+ and CD4+ proportions.
Previous work from our group and others have shown that the CD8 + TIL are
constituted of effector (E) and effector memory (EM) T cells. This demonstration was
based on the original work of Romero P et al. and done in melanoma and other solid
tumors, in freshly isolated CD8+ TIL as well as expanded [99, 107, 109, 147, 296]. When
looking at the four distinct EM populations, using the surface markers CD27 and CD28,
in the CD8+ TIL population of the TIL 3.0 pre-REP versus the final product, we observed
no differences in the CD27 expression Figure 9D. The same observation was made
when comparing the expression in both pre-REP methods (Figure 9E) or post-REP
(Figure 9F) Interestingly, we observed a lower expression of CD28 in the post-REP TIL
3.0 when compared its pre-REP counterpart (mean of 31.6% for pre-REP TIL 3.0 vs
64

9.17% for post-REP TIL 3.0, p=0.0035, Figure 9D). Although not seeing at the pre-REP
level when comparing both expansion methods, we did see this difference at the postREP level, once again when comparing both methods (Figure 9E and 9F). This change
in CD28 expression did not impact the proportion of EM2 and EM3 phenotype in TIL 3.0
post-REP product (Figure 9G, 9H and 9I). Of notes, the EM2 and EM3 are the two most
cytolytic EM fractions[296]. However, the pre-REP TIL 3.0 product comprised of a higher
EM1 (mean of 14.17% vs 4.658%, p=0.019) and EM4 phenotype (mean of 18.717% vs
5.418%, p=0.001, Figure 9G) then the post-REP product suggesting an overall less
differentiated TIL status after the initial expansion when compared to the final one [296].
Further looking into the status of activation/exhaustion status of TIL 3.0 pre and
post-REP, we find a low expression of PD-1 (Figure 9D) independently of the step of
expansion, confirming that the highly proliferative TIL 3.0 were neither terminally
differentiated nor exhausted [297, 298]. A similar observation was made for the TIL 1.0
pre and post-REP product although not surprising giving the lesser proliferation potential
observed with this method (Figure 9E and 9F). The activation status was confirmed with
the high expression of LAG3 at both pre-REP and post- REP level (mean of 66.7% for
pre-REP v/s 84.95% for post-REP TIL 3.0 and mean of 50.53% for pre-REP vs 81.93%
post-REP for TIL 1.0, Figure 9D, 9E and 9F) with a particularly higher expression in the
final product generated with both methods.
Functionality of the TIL is an important feature that can be affected by the state
of differential or activation. Unfortunately, we were not able to generate primary
autologous tumor cell lines from NSCLC tissues to explore the cytolytic potential of the
final product generated with both TIL 1.0 and TIL 3.0 in an autologous fashion. However,
we were still able to measure this potential by looking at their degranulation capacity,
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based on CD107a surface expression upon PMA/Ionomycin stimulation. Both final
product from TIL 1.0 and TIL 3.0 displayed a high degranulation potential (mean of
99.57% vs 99.8%, Figure 9J). When looking at their ability to secrete classical effector
anti-tumoral cytokines such as IFN-γ and TNFα, we also saw no difference between
both final TIL product (mean of 98% for TIL 1.0 vs 99.47% for TIL 3.0 for IFN-γ and
75.76% vs 84.75% for TNFα, Figure 9J). Interestingly, when we repeated the same
experiment on cryopreserved post-REP TIL, we observed for all three post-REP TIL
lines tested that the majority of the TIL still could degranulate but a lower proportion of
could produce IFN-γ (49.2% for TIL 1.0 vs 40.1% for TIL 3.0) and TNFα (13.31% vs
8.5%, Figure 9K) compare to the fresh final products (Figure 9J).
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Figure 9: Characterization of the pre-REP TIL product reveals that TIL 3.0 expanded TIL
are less differentiated than their post-REP counterpart.
(A) Total fold expansion (left axis) of final TIL 1.0 product (red) and TIL 3.0 (blue) (paired, n=6).
Grey circles indicate viability (right axis) above each TIL culture. (B) Comparison of fold
expansion obtained from the final expansion step to generate an infusion product (REP) using
TIL 1.0 (red) and TIL 3.0 (blue) (paired, n=6) at day 14. (C) The percentage of CD3+CD8+ TIL
(left panel) and the percentage of CD3+CD4+ TIL (right panel) (paired, n=6) in the final TIL
product. Assessment of the surface expression of the differentiation/activation CD27, CD28,
PD-1 and LAG3 on (D) pre (solid square) and post-REP (open square) CD8+ TIL (in %)
generated from TIL 3.0 culture (paired, n=6), (E) Pre-REP TIL 1.0 (red solid circle) and pre-REP
TIL 3.0 (solid blue square) (paired, n=6) and (F) Post-REP TIL 1.0 (red hollow circle) and post
REP TIL 3.0 (blue hollow square) (paired, n=6). Comparison of proportion of the four distinct EM
population subsets of (G) pre and post-REP CD8+TIL generated from TIL 3.0 culture (paired,
n=6), (H) Pre-REP TIL 1.0 and pre-REP TIL 3.0 (paired, n=6) and (I) Post-REP TIL 1.0 and post
REP TIL 3.0 (paired, n=6). Analysis of TIL functionality measured by intracellular IFN-γ, TNFα,
co-expression and CD107a on (J) fresh post-REP CD8+TIL and (K) Frozen post-REP CD8+TIL
(in %) upon PMA/Ionomycin activation (TIL 1.0 vs TIL 3.0, paired, n=3).

3.2.5 : The advantages of pre-REP TIL 3.0 in T-cell repertoire richness, high
homology to the tumor as well as high putative tumor-specific TCR content are
not retained after the REP.
We next performed CDR3 variable TCR sequencing on the post-REP TIL product
to assess if the pre-REP homology with the tumor previously found in the TIL 3.0 preREP product was preserved during this final stage of TIL expansion. We first looked at
the richness of the post-REP product and interestingly, although not significant, there
was a reduction in the richness of the TIL 3.0 post-REP product in comparison to what
was initially observed in the pre-REP (median of 2857 for pre-REP vs 1199 for postREP, p=0.07, Figure 10A). In contrast, the TIL 1.0 products started off with lower
richness but the REP expansion did not significantly change their richness although, the
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2 pre-REP TIL 1.0 products that had scored higher in richness were also diminished in
the post-REP products (Figure 10B). In fact, both TIL 1.0 and 3.0 post-REP final
products presented a similar richness (Figure 10C). Inversely, when looking at clonality,
we observed an increase in the TIL 3.0 final product compared to the TIL 3.0 pre-REP
(median of 0.1485 for pre-REP vs 0.2013 for post-REP, p=0.041, Figure 10D). Similarly,
to the richness score, no difference was observed between TIL 1.0 pre and post-REP
clonality score (Figure 10E) or between the clonality of post-REP products generated
from both methods (Figure 10F).
Having observed a drop in richness with a parallel increase in clonality in the final
TIL 3.0 product, we next assessed for a potential impact on the composition of T-cell
repertoire. As shown in Figure 10G, we observed a significant decrease in the Jaccard
index in post-REP TIL 3.0 [median of 0.067 for pre-REP vs 0.0362 for post-REP,
p=0.0089] signifying a decrease in the shared clones between the post-REP TIL product
and the tumor. We did not observe any differences in Jaccard index between the TIL
1.0 pre and post-REP product (Figure 10H) or TIL 1.0 and TIL 3.0 post-REP product
(Figure 10I). When looking not only at the presence but also the relative abundance of
the particular clonotypes with the Morisita Overlap Index (MOI), we saw a significant
decrease in the TIL 3.0 final product compared to pre-REP (median of 0.3968 vs 0.1371,
p=0.0064, Figure 10J). As with the Jaccard index, there was no MOI differences
between TIL 1.0 pre and post-REP (Figure 10K) or TIL 1.0 and TIL 3.0 post-REP product
(Figure 10L). Lastly, when we looked at the putative tumor-specific TCR clones/clusters
retention previously found to be enriched in the TIL 3.0 pre-REP product compared to
the TIL 1.0, we find that this enrichment was not retained in the final expansion (median
of 19.22% for pre-REP TIL 3.0 vs 6.322% for post-REP, p=0.0003, Figure 10M).In
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contrast, the frequency of putative tumor-specific TCR in pre-REP TIL 1.0 was lower,
but mostly retained in the REP, except for the one patient starting off with a higher
frequency (median of 4.875% for pre-REP TIL 1.0 vs 4.219% for post-REP, p=0.6431,
Figure 10N) Consequently, no difference was observed between the frequency of
putative tumor-specific TCR of post-REP TIL 1.0 and TIL 3.0 product (Supplemental
Figure 10O).
Altogether, this data suggests that a second round of expansion (REP) is
detrimental to the great TCR repertoire attributes we reported in the pre-REP TIL 3.0
product including favorable TCR diversity and increased tumor-specific TCR clonal
distribution.
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Figure 10: Post-REP TIL 3.0 does not retain the homology and the putative tumorspecific TCR.
Comparison of TCR richness (paired, n=6) in (A) pre and post-REP TIL 3.0, (B) pre and
post-REP TIL 1.0 and (C) post-REP TIL 1.0 and TIL 3.0. Comparison of clonality (paired,
n=6) in (D) pre and post-REP TIL 3.0, (E) pre and post-REP TIL 1.0 and (F) post-REP TIL
1.0 and TIL 3.0. Comparison of Jaccard Index (paired, n=6) in (G) pre and post-REP TIL
3.0, (H) pre and post-REP TIL 1.0 and (I) post-REP TIL 1.0 and TIL 3.0, Comparison of
MOI Index (paired, n=6) in (J) pre and post-REP TIL 3.0, (K) pre and post-REP TIL 1.0
and (L) post-REP TIL 1.0 and TIL 3.0. Comparison of retained putative tumor-specific
TCR (paired, n=6) in (M) pre and post-REP TIL 3.0, (N) pre and post-REP TIL 1.0 and (O)
post-REP TIL 1.0 and TIL 3.0.

3.3: Summary
This study reports the feasibility of robustly expanding a T-cell repertoire
recapitulating the clonal hierarchy of the T cells in the NSCLC tumor, including a large
number of putative tumor-specific TIL clones, using the TIL 3.0 methodology. We further
report that a second round of expansion does not impart pre-REP expanded through
traditional method. However, this second expansion brings about a drastic alteration in
the pre-REP TIL 3.0 TCR repertoire and it loses all the TIL clonal beneficial attributes of
the pre-REP product. We further advocate, that the pre-REP TIL 3.0 process should be
scaled up and directly infused to the patient. Thus, the robustness and speed of the new
process may facilitate the testing of TIL-ACT approaches in NSCLC.
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Chapter 4: Exploiting Immunosuppressive cytokine TGFβ to enhance anti-tumor
TIL function in solid cancers
4.1: Introduction
Transforming growth factor β (TGFβ) belongs to the TGF superfamily and consists
of three isoforms (TGFβ1, TGFβ2 and TGFβ3). Its role depends on the cell type and
based on the cell, it plays a crucial role in dictating cellular proliferation, apoptosis,
homeostasis of differentiated cells, immune system suppression and cancer progression
[299]. TGFβ is synthesized as an inactive precursor dimer molecule and is secreted into
the extracellular matrix (ECM) as a Large Latent complex (LLC) (Figure 11) [300]. Once
in the ECM, the LLC needs to be cleaved to release the active TGFβ dimer, providing
another layer of control in TGFβ signaling (Figure 11) [301]. This cleavage can happen
either through proteases, integrins, pH or reactive oxygen species [302-304]. The active
TGFβ then relays its downstream signaling effects through the canonical pathway
(mediated through Small Mother Against Decapentalegic (SMADs), red depiction,
Figure 11] and the non-canonical pathway mediated through non-SMADs such as MAP
kinases, PI3K/AKT pathway components and Rho-like GTPase proteins (Cyan
depiction, Figure 11)[305]. Depending on the cell type and aberrations in the signaling
pathway molecules, one TGFβ signaling pathway supersedes the other and results in a
distinct signaling pattern that either suppresses the cells (eg. Immune cell fraction) or
enhances proliferation (eg. cancer cells). In canonical SMAD signaling, TGFβ binds to
a heterodimer complex of the receptors TGFβRII and TGFβRI, with TGFβRI relaying the
downstream signaling through SMAD proteins. These SMAD proteins then translocate
to the nucleus and regulate expression of > 300 genes resulting in cell cycle arrest and
apoptosis in normal and premalignant cells [306] (Figure 11). However, cancer cells
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accumulate mutations in these canonical signaling pathway proteins to bypass TGFβ’s
cytostatic effect [307]. In later stages of cancer progression, TGFβ further facilitates
tumor proliferation and metastasis through non-canonical signaling pathways.

Figure 11: Overview of TGFβ Signaling
On synthesis, TGFβ homodimer interacts non covalently with latency associated peptide (LAP)
forming a small latent TGFβ complex (SLC). This complex then binds covalently to a latent
TGFβ binding proteins (LTBP) forming an inactive Large Latent complex (LLC), that gets
secreted into the ECM. Once, in the ECM, the LLC is cleaved by a host of mechanisms such
as proteases, integrins to release activated TGFβ dimer. This activated TGFβ would then go
on to act on the heterotetrameric TGFβR II and I complex initiating a canonical (SMAD (Red))
or a non-canonical (non-SMAD (cyan)) pathway dependent on the cell type. The canonical
pathway is mediated by SMAD2/3 that further recruits SMAD4. This SMAD complex
translocates to the nucleus and regulates expression of multiple genes. TGFβ can also signal
through non-canonical route mediated by PI3K/AKT, Ras/MAPK, JNK, p38 and RhoA/ROCK
pathways dependent on the cell type and the context. Figure used with permission from R&D
systems.
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Apart from its tumor promoting effects, TGFβ also promotes a more tumorsustaining TME by indirectly modulating it. Cancer cells and multiple cell types including
epithelial cells, stromal, macrophages, leukocytes, endothelial cells all secrete TGFβ
[263, 308]. Along with promoting tumor growth, TGFβ also rescues tumors from
antitumor immunity by directly inhibiting anti-tumor responses through a plethora of
mechanisms. On the adaptive immune fraction side, TGFβ directly suppresses the
cytotoxic potential of T-cells (both CD8+ and CD4+) through repression of cytotoxic
genes such as IFN-γ, perforin, granzyme and genes involved in immune cell proliferation
[309] (Figure 12). Altogether, TGFβ controls two distinct features of adaptive immune
system one; inhibition of cytotoxicity program and secondly inhibiting cellular
proliferation that invariably favors tumor progression [309]. Additionally, TGFβ induces
Foxp3 expression in CD4+ T cells and differentiates them into regulatory T cells (Tregs)
that further inhibit antitumor responses (Figure 12) [310]. TGFβ also impedes NK cell
and B cell proliferation and cytotoxic functions (Figure 12) [311, 312]. Furthermore,
TGFβ regulates myeloid cellular function. It suppresses Dendritic cell maturation and
promotes MDSCs and M2 macrophage development (Figure 12) [313]. MDSCs and M2
macrophages have potent immune suppressive effect. To summarize, TGFβ plays a
critical role in regulating and shaping the TME, tumor progression and immune escape
[313]. Due to such benefits provided by TGFβ for tumor progression and metastasis,
TGFβ signaling is found across most solid tumor types and its serum concentration
correlates directly with the advanced disease and poor survival in multiple cancer types
[307, 314, 315].
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Figure 12: Effect of TGFβ in the TME
TGFβ plays a dichotomous role in cancer progression. In early stages, it suppresses tumor
growth by inducing cell arrest. While in later stages, it actively promotes tumor growth by
inducing its proliferation using non-smad pathways and shaping the TME for its survival.
Every cell in the TME produces and activates TGFβ. These increased TGFβ levels directly
suppress anti-tumor activity by inhibiting T cell, B cell and NK cell activation and
cytotoxicity. TGFβ further prevents maturation of DCs while recruiting potent
immunosuppressive myeloid fraction to the TME. Figure adapted from Wan Jun et al and
used with approval from Copyright Clearance Center License number 5183190531351.
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Because of its far fetching effects both at the local and the systemic levels and
its role in immune escape a a number of strategies are actively being pursued to target
TGFβ. Notable among them are inhibitors of TGFβRI kinase activity (Vactoertib,
Galunisertib), TGFβ directed antibodies and TGFβ ligand traps [316]. Unfortunately,
none of them are efficient as single agents. The interpretation of this clinical data is
complicated by the fact that TGFβ is a pleiotropic factor having both tumor promoting
and tumor suppressing roles. Since the inhibition of TGFβ is not cytotoxic to the tumor
cells, it may benefit to be utilized in combination with other chemo/immunotherapies
[316]. Interestingly, lack of response to anti-PD-L1 therapy (atezolizumab) in metastatic
urothelial cancer patients was further attributed to a signature of TGFβ signaling in
fibroblasts and CD8+ T cell exclusion from the tumor. Blocking of TGFβ using an
antibody in combination with PD-L1 blocking enhanced T-cell infiltration into the tumor
and resulted into anti-tumor activity in in vivo experiments [162, 266]. Because of its
potent immunosuppressive activity on T cells, this portion of my thesis is going to focus
on genetically modifying TIL to rescue/utilize TGFβ for its survival.
4.2: TGFβ Dominant Negative Receptor II (TGFβDNRII)
The strategy that we are exploring for a T-cell targeted inhibition of TGFβ
immunosuppression is to express a decoy receptor for TGFβ in TIL for use in adoptive
cell therapy. TGFβDNRII is a truncated form of WT TGFβ Receptor II (TGFβRII), which
lacks the intracellular signaling domains. The WT TGFβRII extracellular domain enables
the molecule to bind to TGFβ, but the absence of the intracellular domain does not allow
transmission of any downstream signal. Thus, we posit that rendering TIL resistant to
TGFβ with a TGFβDNRII approach will improve their anti-tumor function and result in
better tumor control. This is currently being tested in a clinical trial here in MDACC
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(NCT01955460). TGFβDNRII-transduced TIL-ACT shows clinical activity in the first 9
out 13 treated-patients with metastatic-melanoma validating our hypothesis (Figure
13A). Notably, a majority of these patients were refractory to checkpoint-blockade prior
to receiving TGFβDNRII-transduced TIL-ACT, including a few refractory to CTLA-4 and
PD-1 combination, a patient-population which does not show durable response to the
infusion of non-modified TIL [162]. Efficient inhibition of TGFβ signaling in TIL is likely to
help melanoma patients, but this strategy could be employed in different indications
given the widespread secretion of TGFβ by solid tumors.

However, a number of

responses to TGFβDNRII-transduced TIL-ACT were short-lived suggesting the
emergence of a resistance-mechanism (Figure13B). We intend to understand these
resistance-mechanisms, build upon them and improve upon the shortcomings on the
TGFβDNRII.

Figure 13: Response-kinetics for the first 13 metastatic melanoma patients treated
with autologous TGFβDNRII TIL-ACT
(A) Waterfall plot depicting the best overall response of melanoma patients to TGFβDNRII
TIL-ACT. The response evaluation was performed per the Immune Related Response
Criteria (irRC). (B) Spider plot depicting tumor burden of patients measured over time with
each line depicting a different patient on TGFβDNRII TIL-ACT trial.
78

4.2.1: TGFβDNRII is not stably expressed on cell surface and does not completely
rescue TIL from TGFβ mediated downstream pSMAD signaling
We assessed surface expression of TGFβDNRII over the course of Rapid
Expansion Protocol (REP) after transduction in TIL derived from pancreatic cancer. We
observed the highest TGFβDNRII cell surface expression two days post transduction.
However, this expression was progressively lost with further culturing during the REP
as measured on D7 and D14 of the REP (Figure 14). This suggested that either
TGFβDNRII is not stably expressed on the surface or these cells are lost during the REP
process.

Figure 14: TGFβDNRII is not stable expressed on the cell surface
Representative flow plots of two TGFβDNRII transduced TIL lines over the course of
REP.
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We performed a western blot to detect TGFβRII and report that both Nontransduced (NT) and the TGFβDNRII transduced TIL expressed TGFβRII (Figure 15B),
but this basal level of the receptor is not detected on the cell surface using flow cytometry
(Figure 15A). Interestingly, TGFβDNRII transduced TIL still expressed the truncated
lower molecular weight of TGFβDNRII, but most of it was not expressed on the cell
surface either (Figure 15A and 15B). In order to test its functionality, we assessed the
capability of both the NT and the TGFβDNRII transduced TIL to attenuate TGFβ
mediated downstream pSMAD signaling. We saw that the low levels of this surface
TGFβDNRII expression could attenuate some downstream pSMAD signaling but could
not abrogate it completely. Overall, this suggested that the TIL are transduced with
TGFβDNRII, however it is not stably expressed on the cell surface and is downregulated
with sub-culturing but can attenuate some TGFβ downstream signaling.
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Figure 15: Attenuation of pSMAD2 phosphorylation upon TGF-β engagement in
TGFβDNRII-transduced PDAC TIL.
(A) Surface expression of TGFβDNRII on NT and TGFβDNRII transduced TIL from
patient MP126 at D14 of the REP. (B) Western Blot of TGFβRII, phospho Smad 2
(pSMAD2), total SMAD2 and β-actin of NT and TGFβDNRII-transduced TIL incubated
at 37˚C for the indicated time after exposure to 5ng/ml TGF-β

4.2.2: TIL activation restores surface expression of the transduced TGFβDNRII but
not that of Native TGFβRII and abrogates downstream pSMAD signaling
We hypothesized that the stability of TGFβDNRII expression on the cell surface
is essential to rescue the transduced TIL from TGFβ mediated immunosuppression.
Having ascertained that the TIL express TGFβDNRII within the cell, we next wanted to
determine the factors that regulate its surface expression. We activated TGFβDNRII
transduced TIL with agonistic CD3 antibody and found that TGFβDNRII expression is
restored on the surface (Figure 16A, right panel). Interestingly, we still could not detect
the native TGFβRII surface expression on the surface as observed in the NT TIL (Figure
16A left panel). We next stimulated these TIL with TGFβ and observed that low
TGFβDNRII cell surface expression correlates with attenuation in the pSMAD signaling
(Figure 16A and 16B (right panels). Activation restored the TGFβDNRII surface
expression and completely abrogated downstream pSMAD signaling (Figure 16A and
16B (right panels). Altogether, these findings suggested that TGFβDNRII surface
expression is not stable, is influenced by the activation state of the TIL, and its surface
expression is imperative to rescue TIL from TGFβ mediated immunosuppression.
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Figure 16: Activation restores TGFβDNRII surface expression and abrogates
downstream pSMAD2 phosphorylation upon TGFβ engagement in TGFβDNRIItransduced PDAC TIL.
(A) Surface expression of non-transduced TIL (Left Panel) and TGFβDNRII transduced TIL
(Right Panel) from MP126 before and after activation. (B) Western Blot of TGFβRII, phospho
Smad 2 (pSMAD2), total SMAD2 and β-actin of pre and post activated NT and TGFβDNRIItransduced TIL after exposure to 5ng/ml of TGF-β.

4.2.4: Cloning novel chimeric TGFβDNRII
The WT TGFβRII is a single pass type I transmembrane (TM) protein, 567 amino
acid long with its N-terminus on the extracellular side of the membrane. It consists of an
intracellular kinase domain composed of a di-leucine recycling motif (IL218, IL219 and
Leu 220) and a kinase domain that phosphorylates TGFβRI upon binding TGFβ (Figure
17A) [317]. The di-leucine recycling motif within its intracellular domain helps in TGFβRII
trafficking from the endosomes to the TM and back [317]. The current generation of
TGFβDNRII (cTGFβDNRII) that is used in the clinic consists of a truncation at position
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199 leaving only a 9 amino acid intracellular tail missing both the di-leucine recycling
motif and the kinase domain (Figure 17B). Hence, it can neither recycle from the cell
surface to endosomes nor transduce any signal upon binding to TGFβ. As previously
reported, this cTGFβDNRII transduced TIL is downregulated over time with variable
surface expression depending on the activation state of the TIL (Figure 14,15 and 16).
To overcome this variation in the surface expression, we replaced the signal peptide
(SP) and transmembrane (TM) domain of the WT TGFβRII with that of GM-CSF SP and
a CD28 TM respectively in one construct (CB1, (Figure 17C), and additionally reintroduced the recycling motif (RM) from the WT TGFβRII in the second construct (CB2)
(Figure 17D). We chose the GM-CSF signal peptide because of its reported ability to
sort Type I TM proteins like TGFβRII to the plasma membrane in T cells, while CD28
TM would provide a stable surface expression as observed in Chimeric antigen
receptors [203, 318]. Thus, we hypothesize that this new TGFβDNRII (nTGFβDNRII)
will both stabilize its surface expression and recycle efficiently while lacking the kinase
domain to transduce any signal.
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Figure 17: Cartoon graphics of the TGFβDNRII Constructs
(A) Break down of WT TGFβRII depicting its different motifs. Signaling peptide (SP),
Extracellular domain (ED), Transmembrane domain (TM), Recycling motif (RM) and a
kinase domain (KD). (B) cTGFβDNRII is a truncated version of WT TGFβRII retaining its
SP, ED and TM with a short intracellular amino acid tail ending at 199 aa. (C) CB1 consists
of SP from GM-CSF, retaining the ED of WT TGFβRII and a CD28 TM lacking the
intracellular domain. (D) CB2 consists of CB1 along with the RM of the WT TGFβRII.

4.2.5: Functional assessment of new cloned chimeric TGFβDNRII constructs
reveals no surface expression and no attenuation of TGFβ mediated downstream
pSMAD signaling
We next cloned these constructs in tandem with GFP into Jurkats as a model
line. Jurkats are an immortalized human T cell line that have been extensively used for
studying T cell signaling. Since Jurkats are easy to transduce and handle, we posit that
Jurkats would act as a surrogate to test all these constructs before their assessment in
the patient TIL. As seen in Figure 18A, the cTGFβDNRII in tandem with GFP (control)
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is expressed in Jurkats, demonstrated by the double expression of GFP and TGFβRII,
while the remaining CB1 and CB2 constructs only show GFP expression, but no
TGFβRII was expressed on the cell surface. This result suggests that the Jurkats are
transduced as inferred by their GFP positivity, however TGFβDNRII could not be
detected on the cell surface. We sorted the double population for cTGFβDNRII to study
it further. We next wanted to affirm if the chimeric TGFβDNRII constructs are expressed
and we failed to detect it on the cell surface with flow cytometry. To rule this out, we
performed a functional assay and treated transduced Jurkats with TGFβ. We observed
that only the cTGFβDNRII – GFP could attenuate downstream pSMAD signaling
(MFI:945) while TIL transduced with the other constructs had pSMAD signaling
equivalent to controls [NT treated with TGFβ, GFP transduced TIL with TGFβ
(MFI:1361)] (Figure 18B). This suggested that the chimeric TGFβDNRII constructs were
not expressed on the cell surface and further emphasized that a stable surface
expression is essential to rescue

cells from TGFβ mediated downstream

immunosuppressive signaling.
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Figure 18: Surface expression of novel chimeric TGFβDNRII constructs in
Jurkats and their functional assessment.
(A)TGFβDNRII surface expression of NT (control), cTGFβDNRII, CB1 and CB2.

(B) Representative dot plots of pSMAD positive cells on Jurkats treated for 2 hrs
after exposure to TGFβ (10ng/ml)(Left panel). Bar graph plotting %pSMAD
positive cells across different constructs upon TGFβ stimulation.

4.2.6: Summary
In this sub-chapter, we showed that TIL can be transduced with cTGFβDNRII.
However, its surface expression is not stable, with the highest expression observed
immediately after transduction with subsequent downregulation over time in culture
(REP process). This surface expression is regulated by TIL’s activation status and
surface expression is imperative to attenuate TGFβ mediated downstream pSMAD
signaling. In order to address this surface stability, we designed and cloned two chimeric
TGFβDNRII constructs incorporating findings from the Chimeric Antigen Receptor’s
stability and expression. We replaced the signaling peptide (leader sequence) and the
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Transmembrane domain of the WT TGFβRII with that of GM-CSF and CD28
respectively (CB1) and incorporated the recycling motif of the WT TGFβRII (CB2).
However, none of these new chimeric TGFβDNRII were expressed and consequently
did not have any functionality.

4.3: TGFβ Chimeric-Antigen Receptor (TGFβ-CAR)
The transfer of TGFβDNRII transduced TIL showed durable responses in heavily
pretreated immune-checkpoint refractory melanoma patients in an early stage clinical
trial, validating TGFβ as a target to improve cancer immunotherapy. Rescuing TIL from
immunosuppression improves their function but they still face a deficit of essential costimulatory and cytokine growth signaling in the TME, which may limit their ability to get
activated and perform their effector function in vivo. Providing co-stimulatory and
cytokine signals enhances T cells priming, persistence, survival and effector functions.
Furthermore, engineering co-stimulatory signals into chimeric antigen receptor
molecules (CAR-T) has shown potent anti-tumor effects in preclinical solid-tumor
models and also in clinical setting, with the approval of several CD19 CART products
for B-cell malignancies (NCT03191773 and NCT03076437) [319]. These CAR-T
approaches are providing antigen recognition and costimulation into one molecule. In
the context of TIL therapy, the need is to provide engineered costimulation of TIL while
relying on the endogenous TCR to provide anti-tumor specificity. The premise of this
project is to trigger co-stimulatory signaling in TIL following TGFβ exposure, to ensure
TIL get adequate co-stimulation in the TGFβ rich environments of the tumor, to support
recognition and activation through the native TCR. A TGFβ-CAR engineered to utilize
TGFβ to transmit a costimulatory (signal 2) and cytokine (signal 3) will make TIL less
dependent on DC-based co-stimulation and other external cytokine stimuli, thus
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improving patient outcomes. Furthermore, a TGFβ-CAR will have an enhanced binding
affinity to TGFβ when compared to WT TGFβRII protein. A previous study has shown
the feasibility of targeting soluble cytokines such as TGFβ using CAR [243]. This study
further sheds light on the working mechanisms of the TGFβ-CAR. They report that CAR
signaling to soluble targets such as TGFβ relies on dimerization of the CAR brought
about by the ligand, in this case TGFβ. The signaling downstream of such a TGFβ-CAR
can be fine-tuned by adjusting the mechanical coupling of the antibody binding domain
and the signaling domains [243]. Our TGFβ-CAR will transduce both the co-stimulation
and cytokine support signals that the TIL lack in the TME. Another salient feature of this
CAR construct is that it is not designed to target a particular tumor antigen but uniquely
to provide pro-survival and stimulatory signals. In this sub chapter of my thesis, I will be
focusing on genetically modifying TIL to express TGFβ-CAR to exploit TGFβ for its own
benefit instead of being suppressed by it.
4.3.1: Rationale, cloning and assessing TGFβ-CAR’s surface expression
As shown in Figure 19A, we designed a TGFβ-CAR that encompasses an antiTGFβ ScFv linked to a hinge region (12 amino acid short hinge or from IgG4), a
transmembrane domain and intracellular domain from ICOS, as well as another
signaling domain from 4-1BB and finally a signaling domain from the IL2Rβ. ICOS and
4-1BB co-stimulatory domains were chosen to impart TIL with improved survival and
activation potential. Extensive testing of these domains has been reported in the CART field [79, 84, 195]. ICOS and 4-1BB show a potent anti-tumor effect in preclinical solidtumor models while possessing distinct cytokine secretory profiles [195]. 4-1BB is
predominantly expressed on CD8 T cells, while ICOS plays an important role in CD4
Th1 function. 4-1BB upregulates anti-apoptotic proteins such as Bcl-Xl and Bfl-1,
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prevents AICD, upregulates IL2 and IFN-γ production in CD8 TIL and upregulates IL2
and IL4 from CD4 TIL [96, 97]. ICOS signaling drives CD4 T cells towards a TH1/TH17
phenotype [79], improves cellular persistence in vivo and by extension enhances the
persistence of co-injected CD8 TIL. ICOS can also enhance the persistence and
antitumor activity of injected CAR-T cells [79, 84, 195]. When combined, these
observations suggest that ICOS and 41BB domains will improve TIL survival,
persistence and promote anti-tumor activity [97, 112]. Previous studies also suggest that
adding IL2Rβ domain (signal 3) to the CAR will further support these expanding cells
and cue in the required survival signals [213].
The final TGFβ-CAR design was cloned in tandem with GFP (Figure 19A). We
then transduced the constructs in Jurkats to assess their surface expression. We report
that TGFβ-CAR with IgG Stalk is expressed on the surface, while apart from GFP
expression, we could not track transduction of TGFβ-CAR with 12 amino acids stalk
(Figure 19B). In order to test their surface stability overtime, we next sorted the TGFβCAR with IgG Stalk and observed that it was stably expressed on the surface till the last
of the assessment (Day 26)(Figure 19C).
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Figure 19: TGFβ-CAR Design and their surface expression assessment.
(A) TGFβ-CAR design illustrating the different intracellular domains and their arrangement
in the CAR molecule. GFP is also cloned in tandem with the TGFβ-CAR using a P2A system.
(B) Assessment of the surface expression of NT (control), TGFβ-CAR with a 12 amino acid
stalk and TGFβ-CAR with IgG stalk. (C) Assessment of TGFβ-CAR+GFP+ (upper panel) and
TGFβ-CAR+ (lower panel) surface expression at 7- and 26-days post sorting.

4.3.2: TGFβ-CAR with IgG Stalk abrogates TGFβ downstream pSMAD signaling in
Jurkats and they cannot transmit pSTAT5 signaling on IL-2 stimulation
Having established the stability of TGFβ-CAR with IgG stalk, we next assessed
its capability to abrogate downstream pSMAD signaling on TGFβ stimulation. As seen
in Figure 20A and 20C, TGFβ-CAR with IgG Stalk could attenuate some pSMAD
signaling (MFI:1037), while the 12 amino acid stalk TGFβ-CAR failed to mitigate any
pSMAD signaling upon TGFβ stimulation (MFI:1325) when compared to NT control
(MFI:1361). Interestingly, when we divided the bulk TGFβ-CAR population by gating
separately based on their transduction status, the transduced (GFP+) and Nontransduced (GFP-) cellular fractions had a stark difference amongst their pSMAD
positivity (32.1% for GFP+ (MFI:576) v/s 72.7% for GFP- (MFI 1106), Figure 20B). This
90

suggested that TGFβ-CAR with IgG stalk can bind to TGFβ, prevent it from binding to
the WT TGFβRII and rescue them from downstream TGFβ signaling. We repeated this
experiment on the sorted IgG stalk TGFβ-CAR population and report total abrogation of
pSMAD signaling (Figure 20C).
T cells require cytokine support for persistence and engraftment after infusion.
This requirement has been met historically by high dose of IL-2 administration to
patients. High dose of IL-2 has been known to cause severe toxicities [37, 38]. In order
to ameliorate some of these adverse events, we hypothesized that the expression of a
CAR that can transmit its own cytokine support signaling would lower the dose of IL-2
that needs to be administered to the patient or obviate the need for exogenous IL-2
administration. Previous studies also suggest that adding IL2Rβ signal 3 to the CAR will
support expanding cells and cue in the required survival signals [213]. Hence, we tested
if the expressed CAR could signal the classical IL-2 triggered STAT5 phosphorylation
on our sorted IgG TGFβ-CAR Jurkats with TIL acting as controls. Unfortunately, Jurkats
were not able to transduce any pSTAT5 signaling whether after TGFβ engagement of
the TGFβ-CAR or following exposure to IL-2 (Figure 20D). This underscored the
limitations of using Jurkats as our model line.
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Figure 20: Jurkats transduced with IgG Stalk TGFβ-CAR abrogates downstream
pSMAD but cannot relay pSTAT5 signaling.
(A) Representative dot plots of pSMAD positive cells on different TGFβ-CAR transduced
Jurkats treated for 2 hrs after exposure to TGFβ (10ng/ml). (B) IgG stalk TGFβ-CAR
subdivided based on GFP expression into GFP+ (Transduced) and GFP- (Non-transduced)
and their respective pSMAD expression. (C) Bar graph plotting % pSMAD positive cells
across different TGFβ-CAR constructs upon TGFβ stimulation for 2 hrs. (D) Histogram
depicting pSTAT5 signaling post IL-2 stimulation in TIL (control, left panel) and Jurkats (right
panel).

4.3.3: TGFβ-CAR with IgG Stalk is neither expressed in TIL nor PBMCs and
activation does not upregulate its surface expression
Having shown the proof of principle in Jurkats (TGFβ-CAR surface expression
and abrogation of pSMAD signaling), we next transduced melanoma patient derived TIL
lines with TGFβ-CAR with an IgG stalk using TIL retroviral transduction methodology
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previously optimized by our group [259]. Surprisingly, although all the three tested TIL
lines were transduced (GFP positive), none of them expressed any CAR molecule on
the surface (Figure 21A). Taking a clue from the TGFβDNRII observations, we activated
them with anti-CD3 to check if this upregulated the TGFβ-CAR expression, but it did not
(Figure 21B). We next wanted to ascertain whether the lack of surface expression on
human primary T cells was a TIL specific issue or a T cell issue overall. When we
transduced PBMCs from two different donors along with Jurkats (method control), we
observed that TGFβ-CAR IgG was still not expressed in PBMC but was expressed in
Jurkats (Figure 21C).
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Figure 21: TGFβ-CAR with IgG Stalk is expressed neither on TIL nor PBMC.
Assessment of the surface expression of TGFβ-CAR in (A) resting TIL, (B) Post-activated
TIL with an agonistic CD3 activation and (C) PBMC with Jurkat acting as control.

4.3.4: Modifications to the stalk region of TGFβ-CAR reinstates CAR surface
expression in TIL
N297 amino acid in the CH2 domain of the IgG4 linker used in our CAR has been
previously reported to be glycosylated [320]. Amino acids between 231 -235 (EFLGG)
in the CH2 domain have also been reported to interact with Fc gamma receptors on
innate immune cells resulting in their lower engraftment/persistence in vivo [190].
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Another important aspect that determines CAR characteristics and the resulting
functionality is the binding affinity of the ScFv region of the CAR to its antigen, defined
more specifically by the arrangement of the Heavy (VH) and the light chain (VL) [321].
We re-designed the TGFβ-CAR to integrate all these changes, along with an addition of
a Tag sequence to track our TGFβ-CAR. To circumvent the known limitations of the
IgG4 stalk we first made a single amino acid mutation at N297Q to prevent glycosylation
and replaced EFLGG sequence in the CH2 domain of the IgG4 stalk with a PVA
sequence to avert Fc receptor binding. Secondly, we cloned this IgG*CAR in both VHVL and VL-VH configuration (Figure 22A). Additionally, we cloned a new version of TGFβCAR fitted with a CD8 stalk instead of the IgG4 stalk to circumvent the above mentioned
issues involving the IgG stalk, and we made this new version in both V H-VL and VL-VH
configuration. We also cloned a TGFβ-CAR molecule that was recently reported,
incorporating different intracellular domains (CD28 and CD3ζ) as a control (Figure 22A)
[243]. We then transduced TIL with these TGFβ-CAR variations and assessed their
surface expression. Interestingly, modifications in the CH2 domain of the IgG stalk (now
referred as IgG*) stabilized the surface expression of the TGFβ-CAR for both the VH-VL
and VL-VH configurations. TGFβ-CAR with CD8 stalk and the TGFβ-CAR control were
also expressed on the cell surface (Figure 22B). Surface expression of all of these
TGFβ-CAR constructs along with TGFβDNRII was then confirmed in three TIL lines from
different metastatic melanoma patients (Figure 22C).
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Figure 22: TGFβ-CAR Design and their surface expression assessment.
(A) TGFβ-CAR design illustrating the different iterations of the CAR reflecting two different
ScFv arrangements (VH-VL and VL-VH ) and the linker (IgG* and CD8). Graphical design of
control TGFβ-CAR with its different signaling domains. GFP is cloned in tandem
downstream of the all of these TGFβ-CAR using a P2A system. (B) Assessment of the
surface expression of NT (control) and all the TGFβ-CAR constructs in a TIL line. (C) Bar
graph depicting surface expression of each of these TGFβ-CAR constructs along with a
control TGFβ-CAR and TGFβDNRII across multiple patient derived melanoma TIL lines.

4.3.5: Screening of TGFβ-CARv2 constructs based on their capacity to rescue TIL
from TGFβ mediated pSMAD signaling and their capability to proliferate/survive
in TGFβ
We designed the TGFβ-CAR construct to not only rescue TIL from TGFβ
mediated immunosuppression by blocking the pSMAD downstream signaling, but also
to utilize this TGFβ as a stimulatory and growth cytokine. To evaluate the capacity of
the TGFβ-CAR to rescue TIL from TGFβ, we first assessed its capacity to
attenuate/abrogate pSMAD signaling on TGFβ stimulation. As seen in Figure 23A,
TGFβ caused phosphorylation of SMAD in over 80% of the non-transduced TIL (black
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bars) at all concentrations tested, ranging from 1ng/mL to 10ng/mL. TGFβ-CAR with
CD8 stalk in VL-VH configuration had the best attenuation in pSMAD signaling (blue bar)
where 14% of the GFP positive cells phosphorylated SMAD in comparison to 82% of
the non-transduced TIL following exposure to 1ng/mL TGFβ. It is important to note that
only 35.9% of the TIL were transduced with TGFβ-CAR with CD8 stalk in VL-VH
configuration though the pSMAD phosphorylation of the bulk population was reduced to
24.5%. The non-transduced TIL clearly benefited from the segregation of the TGFβ by
the TGFβ-CAR positive cells demonstrated by the reduction of their phosphorylation of
SMAD from 82% to 35.6%. The TGFβ signaling block was dose dependent. A majority
of the signal from 1ng/mL TGFβ was blocked but as the concentration of TGFβ rose the
TGFβ-CAR molecules became insufficient to bind all the TGFβ and SMAD signaling
ensued in the transduced TIL (GFP positive) as well as the surrounding non-transduced
TIL (GFP negative). TGFβ-CAR with IgG* stalk in VH-VL stalk came in second when
compared to control non-transduced TIL (black bar). This rescue effect diminished with
increasing TGFβ concentrations as well. Since, we could differentiate the transduced
and the non-transduced fraction using GFP, we further assessed each population’s
individual pSMAD signaling. Not surprisingly, transduced populations (GFP+) had the
least signaling (Green Bar) in comparison to Non-transduced fraction (GFP-) (Red Bar),
which in turn had higher signaling than the bulk population (blue bar); albeit still less
than the control (black bar). This established that the TGFβ-CAR could rescue the nontransduced TIL fraction from TGFβ mediated immunosuppression in the bulk population.
We observed the same results when we tested this across multiple TIL lines (Figure
23B). The TGFβ-CAR control and TGFβDNRII however had the most rescue effect.
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Having established that the TGFβ-CAR can rescue TIL from TGFβ mediated
immunosuppression, we next wanted to assess if any of these TGFβ-CAR could utilize
TGFβ for its survival. We propagated the TIL in either IL-2 or TGFβ and tracked its
persistence for 14 days in culture. Strikingly, only the TGFβ-CAR construct with IgG*
stalk in VH-VL configuration was able to sustain survival and growth of TIL when fed with
TGFβ for 14 days (in the absence of IL-2), and showed higher cell numbers than cells
maintained in IL-2 in one cell line (TIL 3334B) or triggered equivalent persistence in
another cell line (TIL 3397) (Figure 23C). Neither TGFβDNRII nor TGFβ-CAR control
transduced TIL persisted when given TGFβ as growth factor. We hypothesized that
since our IgG* VH-VL TGFβ-CAR consist of an IL2Rβ domain, the molecule would signal
for a pro-survival pSTAT5 signal upon TGFβ binding, equivalent to what IL-2 provides
in the culture. However, we could not detect pSTAT5 signaling following TGFβ
stimulation in either resting (Figure 23D left panel) or activated transduced TIL (Figure
23D right panel).
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Figure 23: Screening of TGFβ-CARv2 constructs based on their capacity to rescue TIL from TGFβ
mediated pSMAD signaling and their capability to proliferate/survive in TGFβ
(A) Bar graph depicting percentage of pSMAD positive cells across different TGFβ-CAR
constructs in transduced 3208 TIL. Black bar denotes the pSMAD positive cells in Nontransduced TIL (control), blue bar depicts the bulk population, Green and Red bar represents
transduced (GFP+) and the non-transduced (GFP-) cellular fraction respectively from the bulk
population treated for 2 hrs after exposure to increasing concentrations of TGFβ. (B) Bar
graphs comparing percentage of pSMAD positive cells of bulk population across different
constructs and different TGFβ concentrations in two TIL lines. (C) Bar graph representing TIL
cell count at D14 when propagated in either IL-2 (3000 IU/mL) (Blue) or TGFβ (1ng/mL). (D)
Histogram depicting pSTAT5 signaling post TGFβ (1ng/mL) and IL-2 (1000 IU/mL) stimulation
in resting TIL (control, left panel) and OKT3 activated TIL (right panel).

4.3.6: Rapid Expansion of TIL transduced with TGFβ-CAR with CD8 VL-VH and IgG*
VH-VL reveals they are stably expressed on the surface
We next transduced and expanded our two TGFβ-CAR top constructs (IgG* VHVL and CD8 VL-VH) along with non-transduced (NT) and TGFβDNRII through the
manufacturing process to produce a TIL infusion product for the patient, consisting of a
14-day Rapid Expansion Protocol (REP) following the engineering with TGFβ-CAR
constructs. All cultures expanded adequately in the REP though TGFβDNRII had the
least fold expansion for both TIL lines when assessed on D14 (Figure24A). All the
cultures exhibited over 90% viability (Figure24A).

We also looked at the surface

expression of these constructs across culture duration. We observed that both the CD8
and IgG*TGFβ-CAR are stably expressed throughout the duration (Figure24B). As
previously reported, TGFβDNRII expression is highest after transduction and is
significantly downregulated with REP progression (Figure24B).
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Altogether, this

suggests that both CD8 and IgG* TGFβ-CAR can be expanded to clinical levels and are
stably expressed on the cell surface unlike TGFβDNRII.

Figure 24:Rapid Expansion of TIL transduced with TGFβ-CAR with CD8 VL-VH and
IgG* VH-VL reveals they are stably expressed on the surface.
(A) Total fold expansion of 3381 NT, CD8 TGFβ-CAR, IgG* TGFβ-CAR and TGFβDNRII
(Red Bars, left panel) and in 3390 TIL (blue graph, right panel). The grey circles indicate
viability above each TIL culture. (B) Assessment of TGFβ-CAR and TGFβDNRII surface
expression on different days of REP
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4.3.7: Summary
TGFβ-CAR with IgG stalk is both stably expressed on the surface and can
functionally abrogate pSMAD signaling in Jurkats. However, when transposed to patient
derived TIL or healthy PBMCs, its surface expression disappears. Activating TIL does
not have any effect on its surface expression. Jurkat may act as a surrogate line for a
proof of principle, but it has its own shortcomings and its findings may not truly represent
the biology of a normal T-cell. It has been reported in literature that the IgG stalk can be
glycosylated and bind to Fc receptors on innate cells that can hinder both it’s surface
expression and persistence in vivo [190, 320]. Mutating the IgG domain mitigated these
interactions and made the TGFβ-CAR molecule stably expressed on the cell surface
(now referred as IgG*). We also reported that both the hinge (CD8 and IgG*) and the
ScFv arrangement (VH-VL and VL-VH) have dramatic impacts on the functionality of the
TIL as observed by their varying capacities to rescue TIL from TGFβ mediated
downstream signaling or to utilize TGFβ as a growth factor. Finally, we report that both
the CD8 and IgG* TGFβ-CARs can be expanded to clinically relevant levels and are
stably expressed on the cell surface unlike TGFβDNRII.
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Chapter 5: Discussion
Immunotherapy has brought about a paradigm shift in the way we treat cancer.
The most important change is the ICI revolution that has become the standard of care
in many malignancies such as NSCLC and MM and is currently being expanded to other
cancer types either as a single-agent therapy or in combination with other therapies [67].
As of 2019, FDA has approved 47 immunotherapies that collectively target almost every
major cancer type. Furthermore, there are another 900 immunotherapies in different
phases of clinical trials (Cancer Research Institute). While success has been reported
in highly immunogenic cancer types (referred to as “hot tumors”) such as MM, NSCLC,
immunologically cold solid tumor types such as PDAC have enjoyed little benefits from
ICI. ICIs manipulate the T cells in vivo and rescue them from inhibitory signals, however
the immune cells still need to surmount other immunosuppressive mechanisms present
in the TME to mount an effective anti-tumor response, and certain TME such as
pancreatic cancer are more challenging. Furthermore, the differentiation and the
exhaustion status of the TIL already present in the tumor also plays a critical role when
determining the efficacy of in vivo manipulating treatments [322, 323]. Due to these
shortfalls, approaches where the T cells can be manipulated ex vivo and infused back
to the patients in the form of Adoptive cell Therapy (TIL-ACT) are gaining significance.
TIL-ACT

offers

several

advantages

over

in

vivo

manipulation

with

immunomodulatory agents. Firstly, the T cells are expanded in an environment that
rejuvenates them and restores their highly cytolytic function before being infused to the
patient. Secondly, TIL-ACT is preceded by a lymphodepleting regimen that depletes
both the immunosuppressive Tregs and cells that compete for growth factors and
represent a cytokine sink, making cytokines such as IL-7 and IL-15 available to the
104

infused TIL [134]. TIL-ACT has found success in MM with around 40-50% objective
response rates across different cancer centers across the world [143, 148, 324]. Also, it
has demonstrated activity when infused to patients refractory to CBI in both MM and
NSCLC [162, 167, 169, 325]. Creelan et al, recently reported benefit of TIL-ACT in 11/13
PD-1 refractory NSCLC patients with 3 objective responses including 2 patients having
a complete response for over a year and a half [169]. Despite these successes, there is
still an important fraction of patients who do not benefit from TIL-ACT. Reports from our
group and others have documented the presence of TIL with anti-tumor specificity in
melanoma and other solid tumor types, which is validated by the clinical activity of TIL
ACT regimen with or without checkpoint blockade seen in MM, uveal melanoma,
NSCLC, HPV+ tumors, and anecdotally in breast cancer, ovarian cancer, colorectal
cancer and cholangiocarcinoma [107, 109, 143, 148, 166, 169, 324, 326-330].If TIL do
not lack the ability to recognize and kill the tumor cells, the proportion of anti-tumor T
cells in the final TIL product after ex-vivo expansion has been shown to be low in general
and variable between patients, especially in cold tumor types in comparison to
melanoma, which could be a hurdle to further use of TIL therapy in non-melanoma tumor
types [331-333].
The success of TIL therapy depends in large part on the ability to expand tumorspecific TIL from the tumor tissue, their persistence in the patient after the infusion, their
infiltration to the tumor site and finally their ability to overcome the multiple
immunosuppressive mechanisms that the TME poses to them for killing the tumor.
Previous studies from TIL-ACT have shown that the TIL can indeed persist in the patient
and infiltrate the tumor, while persistence is directly correlated to cancer regression[287,
334]. However, once at the tumor site, these infused TIL may not able to overcome the
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immunosuppression and may become quiescent (the same reason why they could not
eliminate the tumor in the first place).
In this dissertation, I sought to expand a TIL repertoire that has been known to
have characteristics attributed to better patient outcomes with regards to phenotype and
anti-tumor specificity, in my first aim. In my second aim, I sought to increase the fitness
of the TIL product to overcome immunosuppression at the tumor site.
Aim 1. Increasing CD8 content and putative anti-tumor activity of ex-vivo
expanded TIL
For the first portion of my dissertation, we sought to expand a TIL product from
NSCLC tumors (as a model) with attributes known to possess an enhanced anti-tumor
potential. Our study highlights that modifications in the culture conditions of the TIL lead
to measurable changes in the composition of the TIL product as it relates to phenotype
and T-cell specificity. The TIL 3.0 expansion method increased the yield of the desirable
CD8+ TIL fraction as we achieved a median of 81.8 % of CD8+ with TIL 3.0 vs 36.9% for
TIL 1.0 at the initial pre-REP TIL stage. Similar percentages (88.75% of CD8+ with TIL
3.0 vs 41.45% for TIL 1.0) were retained in the final TIL product. The impetus to favor
CD8+ TIL expansion comes from our prior observation that CD8 + TIL content was
associated with better response to TIL therapy in metastatic melanoma [150, 283, 284].
There are indications that CD8+ T cells also play a major role in the clearance of NSCLC,
as evidence shows that increased diversity of the circulating CD8+PD-1+ population pretherapy and their clonal expansion during therapy correlates with response to
checkpoint blockade [335]. The accumulation of dysfunctional CD8+TIL in NSCLC
tumors is on the contrary correlated with resistance to checkpoint blockade approaches
[336]. Thus, the methodology that we report boosts the CD8 + TIL numbers for infusion
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but may also preserves the function of the TIL to be transferred. It has been shown that
T cells exhibiting polyfunctional attributes can mediate superior anti-tumor immune
responses [169, 337, 338]. Here, we report that the expanded TIL product from both TIL
1.0 and 3.0 process also shows polyfunctionality (TNFα and IFN-γ secretion) following
a polyclonal stimulation, as well as anti-tumor cytotoxic potential (degranulation
capacity). Success of the TIL-ACT also depends on the differentiation status of the
infused product [322, 323]. The TIL 3.0 expansion method does not overtly differentiate
cells and prevents exhaustion at the pre-REP stage. Less differentiated TIL are believed
to improve anti-tumor response and persistence post-TIL transfer [339]. However, when
this pre-REP TIL 3.0 cell undergo REP, they tend to differentiate when compared to its
pre-REP status. This observation may be partly attributed to the fact that TIL 3.0 brings
about a higher fold expansion at both the pre and post-REP stage. This is corroborated
from literature which reports that a higher fold expression is biologically coupled to
differentiation [340]. Our findings in TIL 1.0 condition further proves this point; TIL 1.0
undergo a lower degree of expansion and hence maintain their low differentiation status
even after REP. Federico et al, characterized TIL from freshly resected NSCLC tumors
in the same cohort of patients and reported that the NSCLC tumor has abundant TIL
population that are highly proliferative and have an effector/effector memory phenotype.
However, they are functionally impaired with low effector cytokine production along with
high expression of PD-1 and low LAG-3 [341]. TIL 3.0 method provides a strong threepronged stimulation to such functionally impaired TIL and results in unbiased expansion
from the tumor resection. When such cells undergo a high fold expansion, they quickly
differentiate and thus we observe a final product that has a more differentiated TIL
population. Furthermore, we report that our expanded TIL 3.0’s PD-1 and LAG-3
107

expression completely flipped with them losing PD-1 and gaining LAG-3 expression.
This data suggests that the high LAG-3 expression may a result of the expansion
method. A similar finding was reported with TIL expanded using a similar method
including anti-CD3 and anti-41BB in the pre-REP culture in sarcoma where high LAG-3
expression was maintained at both pre and post-REP TIL while PD-1 was significantly
downregulated[342]. Moreover, our TIL has a high cytotoxic potential (CD107a
positivity) and high level of IFN-γ and TNFα effector cytokine secretion despite high
LAG-3 expression levels suggesting that LAG-3 here is most probably an activation
surrogate rather than a true exhaustion marker. It is unclear if interaction of LAG-3 by
its ligand HLA class II would damper TIL cytotoxic potential Conflicting reports are found
in literature with regards to LAG-3 expression alone or its co-expression with PD-1 on
NSCLC TIL and its correlation on outcome [343, 344]. None the less, the expression of
LAG-3 is expected to suppress the function of TIL so one could think of concomitantly
administering anti-LAG3 regimen along with TIL therapy to improve TIL function. Along
this line, inhibition of LAG-3 is currently being evaluated in PD-1 refractory MM patients
(NCT01968109).
TCR sequencing of the TIL found in the tumor resections used for TIL propagation
and their corresponding expanded TIL (pre and post-REP) provided further insight into
the repertoire of TCR specificities that are expanded by the different methods. Poschke
et al. previously reported that pre-REP TIL cultured using the traditional TIL 1.0 method
tend to undergo profound changes in clonal composition from the initial tumor samples
from which the culture was set up both in MM and PDAC [291]. During the initial
expansion process the cultures tend to lose a majority of tumor dominant T-cell clones
or promote outgrowth of T-cell clones that were not prominently present to begin with in
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the tissue. Similar observation was made for NSCLC TIL expansion by Creelan et al.
[169]. They reported that a majority of the expanded clonotypes in the final infusion
product were either present at a lower frequency or not at all in the resected tumor.
Furthermore, only a small fraction of the most prevalent clones was retained in the final
TIL infusion product. They stipulate that TIL clonal contraction within the culture could
partly explain this observation and may have perturbed the “polyvalency” and efficacy
of their TIL product. At the pre-REP level, TIL 3.0 resulted in growth of a more diverse
TIL repertoire when compared to the traditional method which supports the idea of a
more diverse TAA recognition potential. The importance of clonal dominance in the
tumor tissue, in the context of MM, was demonstrated by Pasetto et al. who showed that
the top TIL clones in MM tumor tissue are enriched for tumor specificity and could
mediate an efficient anti-tumor response [292]. This finding supports the idea that T cells
infiltrating the tumor tissue that have an ability to recognize the tumor will clonally expand
and thus will be overrepresented in the TIL population. Altogether these data suggest
that it is critical that the TIL expansion process preserves the high frequency clones
found in the tumor to capitalize on their anti-tumor potential which is what we observed
in TIL 3.0 expanded pre-REP TIL.
As previously mentioned, antigen experienced TIL undergo clonal expansion and
generate memory T cells. These antigen experienced T cells may become functionally
compromised due to persistent chronic antigen exposure in the tumor resulting in T cell
dysfunction [345]. The severity of dysfunction could be a combination of persistence and
extent of this antigenic stimulation inside the tumor [346]. During the initial TIL
propagation from the tumor, I posit that the traditional TIL 1.0 expansion method is not
able to expand this dysfunctional TIL population and that is why we and Poshke et al
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observe the huge alterations in the TIL repertoire between the expanded TIL and the
repertoire initially found in the tumor [262]. TIL 3.0 method provides a strong threepronged stimulation to the TIL that results in unbiased expansion of the TIL repertoire,
including the dysfunctional clones found in the tumor resection. 4-1BB has been
reported to promote T-cell expansion, survival and prevents their apoptosis. This 4-1BB
signaling in the TIL 3.0 not only provides TIL with enhanced proliferation potential, but
also better mitochondrial respiratory capacity and rescues them from activation induced
cell death (AICD), which probably contributes to preserving TCR repertoire diversity
[110, 114, 347, 348]. TIL 3.0 as a result better maintains the frequency of the initial Tcell clones in the expanded TIL and thus retains a stronger homology to the tumor as
we see in our Pre-REP product.
Previous work from our group had shown, in MM, that the proportions of the TCR
vα and vβ families of the TCR repertoire of pre-REP TIL is generally conserved during
the REP [140]. However, this investigation of NSCLC post-REP TIL 3.0 culture with high
throughput TCR CDR3 sequencing demonstrated a drastic reduction in both the clonal
diversity and the homology of the pre-REP product with the tumor, decreasing the
proportion of tumor-specific TIL in the end product. Surprisingly, TIL 1.0 post-REP
product looked similar to its pre-REP product. This drastic reduction was more acute in
the pre-REP TIL 3.0 condition over TIL 1.0 condition. This may be because the second
stage of expansion involves an agonistic CD3 stimulation (TCR signaling) to further
propagate these TIL. Majority of the cells after pre-REP stage expansion become
Effector/Effector memory cells. Further TCR engagement pushes these cells towards
more differentiation and since 4-1BB is absent here, it may result in attenuation of some
of its beneficial AICD rescue effect. We predict this would be more pronounced for TAA
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specific T cells in particular, because they have been clonally expanded previously in
the tumor. Thus, reduction is drastic in TIL 3.0 pre-REP product because it retains a
higher proportion of these TAA specific T cells to begin with. These data call into
question the usefulness of numerically expanding TIL with polyclonal anti-CD3
stimulation in the REP following initial derivation from tumor fragments. Higher numbers
of infused TIL have been associated with better clinical outcome, thus prompting the
refinement of large-scale expansion strategies [162, 349]. However, since patients have
historically been infused with varying number of cells depending on the ability of the TIL
to expand, higher cell numbers may simply have been a reflection of better fitness of the
TIL. Ideally, a smaller number of TIL with increased fitness and more replicative potential
could be infused, allowing for the last phase of expansion to happen inside the
lymphodepleted patient. Evidence that functionally enhanced TIL would require the
infusion of fewer cells to achieve clinical benefit have been reported in the case of TIL
modified to express IL-12 induced following TCR activation [246]. Indeed, 63% objective
clinical response was achieved for IL-12 expressing TIL with the administration of a
single dose between 0.3 and 3.0 billion TIL, which is 10 to 100 times lower than the nonengineered TIL doses currently administered, however the regimen proved toxic for the
patients. TIL 3.0 incorporates TCR activation at the pre-REP stage and delivers a TIL
product with desirable qualities in terms of cytotoxic anti-tumor T-cell content and
proliferative potential in 2 to 3 weeks. The output of cells generated does not match the
number of TIL usually infused for therapy without a second expansion step (REP) but
could be scaled up to reach higher numbers.
Because the potential effectiveness of NSCLC TIL-ACT will be influenced by the
proportion of the tumor-specific TIL infused to the patient, we also employed a
111

computational approach to infer putative TCR specificity through TCR sequencing data,
which concluded that pre-REP TIL 3.0 both preserves and expands a higher proportion
of putative TAA-specific TIL clones. Furthermore, TIL 3.0 was able to expand a majority
of the TAA-specific TIL also found in TIL 1.0 expanded repertoire, but TIL 1.0 failed to
expand as many TAA-specific TIL found in TIL 3.0 at a pre-REP stage. This observation
holds true and can be viewed as an extension of the working principle of TIL 3.0
methodology. As TIL 3.0 contains an anti-CD3 stimulation, all the TIL irrespective of
their antigen recognition would become activated and upregulate 4-1BB in a
synchronous fashion [96]. As TIL 3.0 also contains 4-1BB, its engagement with the
upregulated 4-1BB on the TIL, would prevent AICD and thus we observe a better TIL
clonotype retention. On the contrary, IL-2 provides only a non-specific T-cell cytokine
growth support and hence results in expansion of the most fit T cells over
dysfunctional/exhausted TIL population. This gives credence to why TIL 3.0 harbors a
higher proportion of TAA specific T cells.
Furthermore, since TIL 1.0 method produces a fraction of the cell number as
compared to TIL 3.0 method at the pre-REP stage, it becomes imperative that pre-REP
TIL 1.0 product undergoes a second round of expansion, to produce a large enough
pool of cells required to infuse patients. However, TIL 3.0 produces almost 10 times the
cells compared to TIL 1.0 at pre-REP stage (~300 million). As discussed before, a
second round of expansion for pre-REP TIL 3.0 product results in it detrimental effects
on the anti-tumor T cell content, likely to impact tumor control. All of these observations
advocate for a new one-step process for NSCLC TIL expansion where the initial culture
from tumor fragments is scaled up and patients could get infused with CD8 enriched,
less-differentiated and diverse product within maximum 3 weeks from surgery.
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Since lungs are organs constantly exposed to different external insults, viruses
being one of them, NSCLC tumors also retain a viral-specific T-cell repertoire in addition
to the TAA-recognizing TIL fraction [293-295]. In this current study, we show that TIL
3.0 unbiasedly expands and preserves the TAA-specific T-cell fraction as well as the
virus-specific one found in the NSCLC tumor resections. The latter could be seen as a
drawback for NSCLC TIL-ACT as virus-specific TIL are considered bystanders TIL not
involved in the anti-tumor response. Furthermore, Rosatto P et al. reported that
“dormant” virus-specific TIL could be used as part of an effective anti-tumor response in
mice and ex vivo human models by restimulating these virus-specific TIL with viral
peptides [350]. This reactivation triggered secretion of cytokines such as IFN-, IL-2 and
CXCL10 by the virus-specific TIL which promoted the accumulation of anti-tumor
immune cells such as dendritic cells, NK cells and T cells at the tumor site and
upregulated the peptide presentation machinery in local antigen-presenting cells as well
as tumor cells. In addition, recent work by Chiou et al. reported the cross-reactivity of
TCRs against epitopes derived from NSCLC tumors, Epstein-barr virus, and E. coli
[295]. Overall, this suggests expansion of TIL with pathogen specificity may not
necessarily be detrimental to anti-tumor responses and could perhaps be applied to
harvest a potential “helper” role of bystander TIL in the anti-tumor response.
Creelen et al in their recently published clinical trials expanded their TIL product
with TIL 1.0 or the traditional method, with long culture times which might have increased
the differentiation status of their TIL product. Their final infusion product consisted of a
higher CD4+ TIL fraction, little homology to the initial tumor and retained only a
minuscule fraction of the top ranked TIL clones seen in the tumor. Despite this, they
report that 11/13 patients received some benefit from the TIL-ACT with 2 patients having
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complete responses spanning over one and a half years [169]. We postulate that since
our Pre-REP TIL 3.0 expanded product fares better in putative tumor-specific CD8
content, it would further improve NSCLC outcomes.
In conclusion, our report demonstrates that the pre-REP TIL 3.0 methodology
expands a product that is enriched in CD8+ TIL and shares a significant homology to the
initial TIL milieu. This methodology additionally delivers a TIL product that more faithfully
respects the TIL clonal dominance, preserving the higher frequency of the putative TAAspecific T-cell clones found in the tumor tissue, which is unfortunately lost during the
REP. This last observation advocates for the elimination of the REP and for the
development of a new one-step process for NSCLC TIL expansion where the initial
culture from tumor fragments according to TIL 3.0 process is scaled up and patients are
infused with CD8 enriched, less-differentiated and more diverse product within 3 weeks
from surgery.
Aim 2. Improving TIL fitness; TGFβ signaling blockade
Expanding a TIL product with enhanced cancer eradicating attributes solves one
half of the problem. The other half of the solution to increase responses to TIL-ACT is
to impart fitness to the TIL so as that they survive, persist and mount an effective antitumor response once inside the patient. However, the TME is highly suppressive with
tumor and other cellular fractions secreting multiple immunosuppressive cytokines that
prevents the infiltration, activation, proliferation and the effector functions of the TIL [268,
270]. TGFβ is one such predominant immunosuppressive cytokine that is shared
amongst multiple solid tumor types [351, 352]. TGFβ has been reported to play a role in
resistance to immunotherapy by excluding immune cells from the tumor site, diminishing
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their effector functionality as well as expanding and supporting the growth of regulatory
T cells [268, 270].
Because of such a drastic effect TGFβ has on tumor survival, propagation and
anti-tumor immunity, it has been targeted through multiple mechanisms including
TGFβRI inhibitors, anti- TGFβ antibody and TGFβRII antibodies to prevent TGFβ
binding [316]. All of these in vivo targeted approaches are not specific to the tumor site
and result in systemic side effects and autoimmunity [316]. Additionally, targeting TGFβ
alone only results in cytostatic effect on the tumor. Furthermore, this approach would
require continued administration as the inhibitors would be subsequently cleared from
the body. We posit that the targeted blocking of TGFβ signaling in TIL through genetic
engineering will maximize their anti-tumor function when they home back to the tumor
while minimizing systemic side effects for the patient. Another advantage of this
approach is genetically modifying TIL ensures that not only the transduced TIL, but their
progeny would also retain these functional capabilities and continue to function
unabated.
A TGFβ dominant negative receptor has been shown to rescue TIL from
immunosuppression in an ongoing clinical study here at MD Anderson Cancer Center
and has resulted in durable responses in a subset of CBI refractory MM patients [251,
353]. When we transduced melanoma pre-REP TIL with TGFβDNRII, we observed that
the expression of the construct is highest after T-cell activation but is progressively lost
with further subculture, with only a tiny fraction of the original expression retained at the
end of the REP (D14) or the final TIL product infused to the patient. We report that this
expression is not enough to efficiently abrogate TGFβ downstream signaling, leaving
them unprotected from TGFβ. This suggests that even after genetically modifying
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TGFβDNRII into the TIL, the TIL can only be protected from TGFβ signaling in the
presence of a simultaneous TCR activation. We further show that polyclonal anti-CD3
stimulation reinstates the TGFβDNRII expression without inducing the expression of the
WT TGFβRII. We hypothesize that this maybe because as TGFβDNRII is a truncated
version of the native TGFβRII, it might follow the same kinetics of expression as the
native TGFβRII. Native TGFβRII is not detected on the cell surface by flow cytometry,
but still relays the downstream pSMAD signaling [305]. Western blot results show that it
is present in the cell. We believe that a tiny fraction of TGFβRII is present on the surface
(below detection threshold of flow cytometry) while the remaining majority of the protein
is either continuously being cycled to and from the cell surface and the endosomes or
present in vesicular pools close to the cell membrane. We believe that since TGFβDNRII
follows the same kinetics most of the expressed protein would be present just below the
cell surface since it lacks the recycling motif required for trafficking between the cell
membrane and the endosomes. TGFβ is referred as the “guardian of T-cell function”
and tightly regulates their homeostasis [354]. TIL activation thus quickly translocates
this reserved pool below the cell membrane to the surface to notch down the activation
and revert back to a state of homeostasis. This theory also explains why we detect a
high TGFβDNRII expression few days after transduction because TIL activation occurs
just a day prior to transduction as part of the transduction protocol [355]. Thus, as the
activation wanes off with time in culture, so does the TGFβDNRII expression, suggesting
a direct correlation between the activation status and its surface expression.
Although we infuse billions of TILs to the patient, only a small fraction of these
cells would be TAA specific and would be able to activate upon recognizing their target
antigen. The infused TIL would have to navigate through the circulatory system, reach
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the TME and only then would it find its target. Both the patient serum and the local TME
contain high TGFβ concentrations that the TIL need to face before reaching the tumor.
During the entire time required for trafficking to the tumor tissue, TIL would be in close
proximity with TGFβ and thus would be suppressed by the time it makes it to the tumor.
Another caveat is that TGFβDNRII was designed to act as a sink for TGFβ and quench
it away from other cellular fractions. This is observed only when TIL stably expresses
TGFβDNRII. Altogether, this suggest that a stable TGFβDNRII is imperative for its
functionality and a TIL infusion product with low TGFβDNRII would not fare better than
the non-transduced TIL infusion product.
We sought to stabilize the TGFβDNRII expression in my second part of the thesis.
Hypothesizing that since TGFβDNRII bears a lot of resemblance to the WT TGFβRII
and follows its kinetics, I sought to replace the signaling peptide and the transmembrane
domain of the receptor while retaining the TGFβ binding ectodomain of the receptor in
order to break away from its natural kinetics and in the process stabilize its surface
expression. The signaling peptide shuttles the protein to its destination in the cell. We
decided to test the replacement of the signaling peptide by a GM-CSF signaling peptide
that has been reported to shuttle proteins to the cell surface [318]. We additionally chose
a transmembrane domain from CD28 that has been known to stabilize the surface
expression [203]. With this rationale, we cloned and transduced multiple novel chimeric
TGFβDNRIIs to incorporate these different elements into Jurkat cells acting as a
surrogate cell line. Interestingly, apart from the initial TGFβDNRII construct, none of the
new chimeric TGFβDNRII were expressed or had any function. Since, these chimeric
proteins is a conglomerate of multiple different domains belonging to different proteins,
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there is a high chance that it would have not folded correctly and might have been
degraded. Our attempts to decipher this by western blotting weren’t conclusive.
This prompted us to approach this problem with a different angle. We considered
blocking TGFβ signaling by expressing a TGFβ antibody on TIL and use this opportunity
to build a CAR construct that would not only bind TGFβ but actually use TGFβ to
promote TIL activation and expansion. We postulated that if a TGFβDNRII could have
dramatic effects in tumor control in patients, a CAR molecule designed to exploit TGFβ
for TIL survival and stimulation would enhance the patient responses further. A TGFβtargeting CAR molecule was recently published by Chang et al et al, where they
designed a TGFβ-CAR with CD28 and CD3 endodomains and proved its feasibility
[243]. We intended to use different endodomains to specifically support TIL activation
needs. We cloned the same ScFv region from this TGFβ-CAR molecule in our new
constructs because it had been proven to bind to TGFβ and would help us develop a
system where we can test multiple variations in our hinge region and the intracellular
domains keeping the binding affinity constant [243]. Two factors differentiate our TGFβCAR molecule from other CAR approaches; first it is not designed to re-direct the TIL to
target any particular tumor antigen, and second, it lacks a CD3ζ domain to trigger
cytotoxicity. In contrast, our TGFβ-CAR is designed to provide co-stimulation and a builtin growth factor signal to TIL, to potentiate the endogenous TCR signal. Engagement of
the TGFβ-CAR by TGFβ in the absence of TCR engagement is not expected to trigger
TIL activation. Since there is a ton of TGFβ in the plasma and TME of the patient, this
would ensure that the transduced TIL with TGFβ-CAR are not constitutively activated,
exhaust and undergo apoptosis. Nonetheless, the cytokine signaling built into the TGFβCAR construct may be able to sustain antigen-independent TIL expansion and remove
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the need to provide exogenous cytokine in TGFβ rich environments. One of the tested
TGFβ-CAR constructs was able to sustain TIL growth using TGFβ as a growth factor
which is encouraging. Moreover, TGFβ-CAR transduced TIL would solely depend on its
TCR for antigen recognition, which we hypothesize would most likely happen at the
tumor site (since TIL recognize mainly tumor antigens), in the presence of TGFβ, which
will trigger a costimulatory signal through TGFβ-CAR. Optimal costimulation at the tumor
site has the potential to decrease the threshold for TIL activation, presumably enlarging
the pool of TIL successfully activated at the tumor site and augmenting anti-tumor
function. Since TIL consist of a diverse population with multitude of TCR’s it ensures a
broad reactivity against the tumor. Solid tumors are a heterogenous population with a
varied expression of the targeted antigens. Antigen loss has been reported as a
mechanism of resistance to traditional CAR-therapy targeting one tumor antigen [218].
Since, TIL-ACT has been previously reported to eradicate complete tumors, transducing
a TGFβ-CAR would only increase its effectiveness and improve patient outcomes.
With this rationale, we designed the first two TGFβ-CAR constructs with a short
12 amino acid hinge region or an IgG hinge and tested them in Jurkats. We reported
that the 12 aa was not expressed in the Jurkats and could not rescue TIL from TGFβ
signaling (pSMAD signaling). TGFβ-CAR with the IgG hinge was both stably expressed
and could rescue Jurkats from downstream pSMAD signaling upon TGFβ stimulation.
Jurkat being a tumor line is independent of the cytokine signaling essential for a healthy
T cell survival and is refractory to IL-2 signaling. This made it not suitable to test the
pSTAT5 signaling function of the cytokine domain of the CAR. Surprisingly, this same
IgG stalk TGFβ-CAR was not expressed in either healthy PBMCs or TIL. IgG stalk in
our construct has been reported to be glycosylated in T cells and may have resulted in
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its degradation [320]. This may explain why it was not observed on the cell surface.
Jurkat being a cancer line glycosylates protein differently than healthy T cells and hence
it could express the TGFβ-CAR while the healthy TIL/PBMC could not. Mutating the
amino acids known to be glycosylated resulted in reinstatement of the TGFβ-CAR
expression in TIL [190, 320].
Chi N et al. recently demonstrated that the arrangement of the heavy (V H) and
the light chain (VL) in the ScFv also plays a crucial role in determining the CAR’s
binding[321]. In addition, from our results we further observe that the choice of the
hinge/stalk region influences the binding affinity of the ScFv region too. We observed
this first hand when we report that the TGFβ-CAR with IgG* stalk (mutated IgG Stalk)
functioned the best when it was in the VH-VL configuration, while the TGFβ-CAR with
CD8 stalk functioned optimally when it was in the VL-VH configuration. CD8 stalk is
relatively short (45 amino acids) when compared to IgG* stalk (216 aa). The length of
the stalk region may result in stearic hindrance for the ScFv to properly bind the TGFβ
and maybe favor one arrangement of heavy and light chain over the other. Chang et al,
reported that TGFβ mediated dimerization exerts a mechanical tensile force that is
relayed on to the intracellular signaling domains. This mechanical coupling between
ScFv and the intracellular signaling domains could be fine-tuned to dictate the behavior
of the CAR. They further report that an increase in the length of the stalk inversely
correlates to the activation potential while it requires a higher TGFβ concentration to
transduce a signal [243]. We report that TGFβ-CAR with the CD8 stalk was the best at
rescuing TIL from TGFβ mediated immunosuppression by blocking pSMAD signal while
TGFβ -CAR with the IgG* stalk was the most efficient in relaying a growth signal when
cultured with TGFβ. This finding was surprising in the regards that we predicted that the
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smaller CD8 stalk rather than the longer IgG* stalk would be the most efficient at
transducing the co-stimulatory signal as well. One potential explanation for this
observation is may be that CD8 stalk is too short and hence rigid to afford any flexibility
to relay an activating signal inside the cell. In addition, because of its smaller length, the
CD8 stalk TGFβ-CAR would be proximal to the cell membrane and would directly
compete with the TGFβRII since they are in the same geospatial space. This may be
one of the reasons as to why CD8 stalk is better at rescuing TIL from TGFβ mediated
signaling. The IgG* spacer stalk being ~4.5 times longer than the CD8 stalk, it protrudes
far away from the cell surface hence is not able to directly compete with the TGFβRII.
This IgG spacer stalk’s longer length thus affords the flexibility to relay the signal. We
further cloned the TGFβ-CAR that was reported by Chang et al. as a positive control
and TGFβDNRII as a comparator for our study. As perceived, both TGFβDNRII and the
control TGFβ-CAR rescued the TIL from TGFβ mediated signaling. In addition, TIL
transduced with TGFβDNRII could not persist in TGFβ-containing media when not
supplemented with IL-2, which is not surprising. Of note, it was interesting to see that
the expression of the control TGFβ-CAR did not allow TIL to persist either in the TGFβ
supplemented media. This may be because the control TGFβ-CAR was developed in
the healthy PBMCs. PBMCs are mainly composed of naïve T cells that have never faced
any sort of immunosuppression as opposed to antigen experienced Effector/EM TIL.
Additionally, the control TGFβ-CAR comprises of a CD28 and CD3ζ signaling domains,
known to push TIL towards exhaustion and ultimately apoptosis. We predict this
continuous CD3ζ signaling from the TGFβ-CAR in TIL here would have resulted in them
undergoing apoptosis and hence poor persistence.
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We next reported that both the IgG* and the CD8 CAR were stably expressed
throughout the REP culture with TGFβDNRII precipitously downregulating its surface
expression at the end of the REP and it did not impact total fold expansion. As previously
discussed, TGFβDNRII surface expression is imperative for its functionality. The TGFβCAR that we designed are stable and since they can rescue TIL from downstream
signaling can act as a Dominant negative Receptor in itself. Since, TGFβ-CAR is
designed with an IL2Rβ domain, we postulated that the growth advantage that we
observed in the TGFβ culture media was because it could transmit a downstream
pSTAT5 signal from TGFβ. However, to our surprise it was not the case. Activating the
TIL did not alter pSTAT5 levels either. Future work needs to focus on RNA sequencing
the TIL transduced with TGFβ-CAR and stimulated in presence or absence of TGFβ to
tease

out

the

molecular

underpinnings/pathways

that

result

in

TGFβ-CAR

proliferating/surviving in the TGFβ medium. In the end, the most important readout of
the efficacy of the TGFβ-CAR is its capacity to kill the tumor cells. Experimental efforts
focusing on the need to evaluate the cytotoxic potential of these TGFβ-CAR TIL would
further prove our theories.
In conclusion, our work here touches on two important aspects that contributes
immensely to the success of TIL-ACT Therapy. In the first portion, we focused on
expanding the right TIL product from the patient resection. We show that using our novel
TIL expansion method employing the three signals for proper T-cell activation (TIL 3.0)
successfully expands TIL from 100% NSCLC tumor tissues tested, consistently
augments the yield of expanded TIL as well as their proportion of putative anti-tumor
TCR, at the pre-REP, while reducing the manufacturing time when compared to the
traditional IL-2 method (TIL 1.0) in resected early-stage NSCLC tumors. In the second
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part, we focus on enhancing the fitness of these expanded TIL. We showed a proof of
principle

study

in

which

we

designed

TGFβ-CAR

that

could

exploit

an

immunosuppressive cytokine (TGFβ) and utilize it to promote TIL activation and survival.
Our studies identified one functional candidate construct. TIL transduced with this TGFβCAR construct could be expanded to clinically relevant numbers. More work is needed
to assess the full functional impact of this construct on TIL. Overall this project has laid
out a framework to enhance the potency of TIL products in future TIL ACT studies.
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